
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/base_style-CPPDhfna.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-BepKMsUl.js"></script>

  <link rel="stylesheet" href="/static/assets/article_style-DUfI1jZp.css" />
<link rel="stylesheet" href="/static/assets/style-BOrsu84o.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-D3wJHomh.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="E0CA252F930B0E0300252F00264B4F54.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="dmj">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12270588/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Diabetes &amp; Metabolism Journal">
<meta name="citation_title" content="Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning">
<meta name="citation_author" content="Jung A Kim">
<meta name="citation_author_institution" content="Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea">
<meta name="citation_author" content="Hye Jin Yoo">
<meta name="citation_author_institution" content="Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea">
<meta name="citation_publication_date" content="2025 Jul 1">
<meta name="citation_volume" content="49">
<meta name="citation_issue" content="4">
<meta name="citation_firstpage" content="525">
<meta name="citation_doi" content="10.4093/dmj.2025.0242">
<meta name="citation_pmid" content="40631457">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12270588/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12270588/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12270588/pdf/dmj-2025-0242.pdf">
<meta name="description" content="Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated considerable efficacy in the treatment of diabetes and obesity, it is essential to recognize that their use is associated with certain intrinsic risks that must not be ...">
<meta name="og:title" content="Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated considerable efficacy in the treatment of diabetes and obesity, it is essential to recognize that their use is associated with certain intrinsic risks that must not be ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12270588/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://pmc.ncbi.nlm.nih.gov/search/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12270588">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.4093/dmj.2025.0242"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/dmj-2025-0242.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12270588%2F%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12270588/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12270588/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12270588/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-dmj.gif" alt="Diabetes &amp; Metabolism Journal logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Diabetes &amp; Metabolism Journal" title="Link to Diabetes &amp; Metabolism Journal" shape="default" href="http://e-dmj.org/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">Diabetes Metab J</button></div>. 2025 Jul 1;49(4):525–541. doi: <a href="https://doi.org/10.4093/dmj.2025.0242" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.4093/dmj.2025.0242</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://pmc.ncbi.nlm.nih.gov/search/?term=%22Diabetes%20Metab%20J%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Diabetes%20Metab%20J%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22Diabetes%20Metab%20J%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22Diabetes%20Metab%20J%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kim%20JA%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Jung A Kim</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Jung A Kim</span></h3>
<div class="p">
<sup>1</sup>
Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Kim%20JA%22%5BAuthor%5D" class="usa-link"><span class="name western">Jung A Kim</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yoo%20HJ%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Hye Jin Yoo</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Hye Jin Yoo</span></h3>
<div class="p">
<sup>1</sup>
Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yoo%20HJ%22%5BAuthor%5D" class="usa-link"><span class="name western">Hye Jin Yoo</span></a>
</div>
</div>
<sup>1,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="af1-dmj-2025-0242">
<sup>1</sup>
Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea</div>
<div class="author-notes p"><div class="fn" id="c1-dmj-2025-0242">
<sup>✉</sup><p class="display-inline">Corresponding author: Hye Jin Yoo https://orcid.org/0000-0003-0600-0266 Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine, 148 Gurodong-ro, Guro-gu, Seoul 08308, Korea E-mail: <span>deisy21@korea.ac.kr</span></p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Mar 24; Accepted 2025 May 30; Issue date 2025 Jul.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>Copyright © 2025 Korean Diabetes Association</div>
<p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<a href="https://creativecommons.org/licenses/by-nc/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by-nc/4.0/</a>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12270588  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40631457/" class="usa-link">40631457</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<p>Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated considerable efficacy in the treatment of diabetes and obesity, it is essential to recognize that their use is associated with certain intrinsic risks that must not be disregarded. The incidence of adverse effects, particularly gastrointestinal complications, psychiatric disorders, and ocular problems, highlights the critical need for thorough patient assessment and continuous monitoring to ensure both the safety and effectiveness of treatment. Despite the possibility of adverse events, GLP-1 RAs continue to represent a crucial therapeutic modality for metabolic disturbances. This highlights the significance of ongoing research initiatives aimed at optimizing their safe utilization and refining current treatment protocols to improve patient outcomes. This review summarizes updated research findings regarding the adverse effects of GLP-1 RAs, their mechanisms of action, and guidelines for clinical application.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> Biliary tract diseases, Drug-related side effects and adverse reactions, Eye diseases, Gastrointestinal diseases, Glucagon-like peptide-1 receptor agonists, Mental disorders, Pancreatic diseases, Sarcopenia</p></section></section><section id="sec1"><h2 class="pmc_sec_title">KEY FIGURE</h2>
<figure class="fig xbox font-sm" id="f2-dmj-2025-0242"><p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cf2/12270588/2c0f4558a2d2/dmj-2025-0242f2.jpg" loading="lazy" height="677" width="716" alt="graphic file with name dmj-2025-0242f2.jpg"></p>
<div class="p text-right font-secondary"><a href="figure/f2-dmj-2025-0242/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure></section><section id="sec2"><h2 class="pmc_sec_title">Highlights</h2>
<section class="bt xbox font-sm" id="boxed-text1"><p>• GLP-1 RAs demonstrate metabolic efficacy but present diverse adverse events.</p>
<p>• GI effects are common; obstruction or perioperative aspiration are major concerns.</p>
<p>• GLP-1 RAs link to gallbladder/biliary diseases without increasing pancreatitis risk.</p>
<p>• Close monitoring is essential for depression and suicidal ideation during therapy.</p>
<p>• Retinopathy, NAION, cancer, and sarcopenia warrant careful consideration.</p></section></section><section id="sec3"><h2 class="pmc_sec_title">INTRODUCTION</h2>
<p>The first incretin hormone, gastric inhibitory peptide, was identified in the early 1970s, followed by the discovery of glucagonlike peptide 1 (GLP-1) in the 1980s [<a href="#b1-dmj-2025-0242" class="usa-link" aria-describedby="b1-dmj-2025-0242">1</a>]. In the 1990s, exendin-4, a GLP-1 receptor agonist (GLP-1 RA) structurally similar to endogenous GLP-1, was isolated from Gila monster venom, which subsequently led to the approval of exenatide for type 2 diabetes mellitus (T2DM) management in 2005 [<a href="#b2-dmj-2025-0242" class="usa-link" aria-describedby="b2-dmj-2025-0242">2</a>]. Since then, GLP-1 RAs have attracted considerable academic interest, leading to the continuous introduction of innovative analogs into the pharmaceutical industry. These pharmacological agents exhibit beneficial effects on glycemic regulation, weight management, and cardiovascular outcomes, thereby establishing their essential roles in contemporary diabetes management [<a href="#b3-dmj-2025-0242" class="usa-link" aria-describedby="b3-dmj-2025-0242">3</a>-<a href="#b5-dmj-2025-0242" class="usa-link" aria-describedby="b5-dmj-2025-0242">5</a>]. To date, dulaglutide, semaglutide, and tirzepatide have been the three predominant GLP-1 therapeutics employed in the treatment of T2DM, and their applications have been broadened to include weight management. In December 2014, the Food and Drug Administration (FDA) approved liraglutide for weight loss, and semaglutide was approved for diabetes in 2017 and obesity in 2021, opening a new era of obesity treatment. Currently, intense media attention and influencer promotion, coupled with robust marketing tactics, have led to an increase in the demand for GLP-1 RAs, resulting in global shortages of these medications. Despite their considerable benefits, GLP-1 RAs are associated with various adverse reactions (<a href="#f1-dmj-2025-0242" class="usa-link">Fig. 1</a>). This study aimed to critically assess the existing literature on the adverse effects of GLP-1 RAs to formulate appropriate risk-benefit prescription practices for their optimal utilization as metabolic disease therapeutics.</p>
<figure class="fig xbox font-sm" id="f1-dmj-2025-0242"><h3 class="obj_head">Fig. 1.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12270588_dmj-2025-0242f1.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cf2/12270588/90011d08c7c9/dmj-2025-0242f1.jpg" loading="lazy" height="579" width="610" alt="Fig. 1."></a></p>
<div class="p text-right font-secondary"><a href="figure/f1-dmj-2025-0242/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>An overview of the existing literatures on the adverse effects linked to glucagon-like peptide-1 receptor agonists (GLP-1 RAs) across diverse research methodologies: Pink circle (<sup><img class="inline" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cf2/12270588/97730cc4d743/dmj-2025-0242i1.jpg" loading="lazy" alt="Inline graphic"></sup>) denotes the existence of research indicating that GLP-1 RAs increased the incidence of such adverse effects; Blue circle (<sup><img class="inline" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cf2/12270588/efa747e95ce2/dmj-2025-0242i2.jpg" loading="lazy" alt="Inline graphic"></sup>) denotes the existence of research indicating that GLP-1 RAs decreased the incidence of such adverse effects; Orange circle (<sup><img class="inline" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cf2/12270588/15168908345a/dmj-2025-0242i3.jpg" loading="lazy" alt="Inline graphic"></sup>) denotes the existence of research indicating that GLP-1 RAs was not significantly associated with such adverse effects; Grey circle (<sup><img class="inline" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1cf2/12270588/2a830de233ad/dmj-2025-0242i4.jpg" loading="lazy" alt="Inline graphic"></sup>) denotes an absence of research concerning the correlation between GLP-1 RAs and such adverse effects. The superscript numerals of each circular element indicate the corresponding referenced studies. RCT, randomized controlled study; RWD, real-world data; SRS, spontaneous-reporting system; NAION, non-arteritic ischemic optic neuropathy; GB, gallbladder. <sup>a</sup>RWD: real-world data from cohort or registry studies (electronic health records, insurance-claims databases), <sup>b</sup>SRS: adverse drug reaction evidence from case reports and spontaneous-reporting systems, such as the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) and World Health Organization (WHO) VigiBase.</p></figcaption></figure></section><section id="sec4"><h2 class="pmc_sec_title">GASTROINTESTINAL ADVERSE EFFECTS</h2>
<p>The most prevalent adverse effects associated with GLP-1 RAs include gastrointestinal disturbances, such as nausea, vomiting, diarrhea, and constipation [<a href="#b6-dmj-2025-0242" class="usa-link" aria-describedby="b6-dmj-2025-0242">6</a>,<a href="#b7-dmj-2025-0242" class="usa-link" aria-describedby="b7-dmj-2025-0242">7</a>]. These symptoms frequently manifest during the initial treatment phase, affecting approximately 50% to 60% of patients [<a href="#b8-dmj-2025-0242" class="usa-link" aria-describedby="b8-dmj-2025-0242">8</a>], but they generally diminish over time, with their occurrence being dose-dependent. The capacity of GLP-1 RAs to decelerate gastric emptying to levels indicative of gastroparesis raises concerns regarding potential intestinal obstruction and perioperative aspiration risk.</p>
<section id="sec5"><h3 class="pmc_sec_title">Evidence based on recent studies</h3>
<section id="sec6"><h4 class="pmc_sec_title">Intestinal obstruction</h4>
<p>Initially, cases of intestinal obstruction associated with GLP-1 RAs were reported by the European Medicines Agency (EMA) in 2013 [<a href="#b9-dmj-2025-0242" class="usa-link" aria-describedby="b9-dmj-2025-0242">9</a>], and this safety signal is currently being monitored by the United States (US) FDA. Based on VigiBase, the World Health Organization’s (WHO) adverse drug reaction database, intestinal obstructions are reported over 4.5 times more frequently with incretin-based drugs than with other diabetes medications [<a href="#b10-dmj-2025-0242" class="usa-link" aria-describedby="b10-dmj-2025-0242">10</a>]. Similarly, an analysis utilizing the UK Clinical Practice Research Datalink (CPRD) revealed that GLP-1 RAs were linked to an increased incidence of intestinal obstruction requiring hospitalization, compared to sodium-glucose cotransporter-2 (SGLT-2) inhibitors (1.9 vs. 1.1 per 1,000 person-years; hazard ratio [HR], 1.69; 95% confidence interval [CI], 1.04 to 2.74) [<a href="#b11-dmj-2025-0242" class="usa-link" aria-describedby="b11-dmj-2025-0242">11</a>]. In contrast to these results, a study using nationwide registry data from Sweden, Denmark, and Norway—involving 121,254 new GLP-1 RA users and 185,027 new SGLT-2 inhibitor users— documented 557 intestinal obstruction events, with no significant correlation between GLP-1 RA use and increased intestinal obstruction risk, thereby refuting earlier safety concerns [<a href="#b12-dmj-2025-0242" class="usa-link" aria-describedby="b12-dmj-2025-0242">12</a>]. Nielsen et al. [<a href="#b13-dmj-2025-0242" class="usa-link" aria-describedby="b13-dmj-2025-0242">13</a>] recently reported that GLP-1 RAs are not associated with an increased risk of intestinal obstruction in patients with inflammatory bowel disease using Danish health registries. While some studies suggest a possible correlation between GLP-1 RAs and intestinal obstruction, others report no significant association, with discrepancies likely due to variations in study demographics, methodologies, and GLP-1 RA formulations. Therefore, more extensive randomized controlled trials (RCTs) are essential to elucidate these relationships and inform clinical practice.</p></section><section id="sec7"><h4 class="pmc_sec_title">Aspiration occurring during procedural anesthesia</h4>
<p>The correlation between delayed gastric emptying and GLP-1 RAs raises concerns about the possible negative effects in the periprocedural setting, as evidenced by case reports of aspiration events occurring during procedural anesthesia in patients administered GLP-1 RAs [<a href="#b14-dmj-2025-0242" class="usa-link" aria-describedby="b14-dmj-2025-0242">14</a>,<a href="#b15-dmj-2025-0242" class="usa-link" aria-describedby="b15-dmj-2025-0242">15</a>]. Studies on patients taking GLP-1 RAs have demonstrated increased gastric residue on esophagogastroduodenoscopy [<a href="#b16-dmj-2025-0242" class="usa-link" aria-describedby="b16-dmj-2025-0242">16</a>]. A prospective study involving individuals initiated on semaglutide, evaluated via ultrasound after an overnight fast, demonstrated that 70% of those receiving semaglutide exhibited retained solid gastric content, in contrast to 10% in the control group [<a href="#b17-dmj-2025-0242" class="usa-link" aria-describedby="b17-dmj-2025-0242">17</a>]. Nersessian et al. [<a href="#b18-dmj-2025-0242" class="usa-link" aria-describedby="b18-dmj-2025-0242">18</a>] also reported that preoperative semaglutide use within 10 days of elective surgery was independently associated with increased residual gastric content, as assessed by gastric ultrasound. In the semaglutide group, 40% of patients exhibited increased residual gastric content, compared to only 3% of non-semaglutide users [<a href="#b18-dmj-2025-0242" class="usa-link" aria-describedby="b18-dmj-2025-0242">18</a>]. Another cross-sectional study prospectively recruited patients adhering to preprocedural fasting protocols before elective anesthesia revealed that, after controlling for confounding variables, the use of GLP-1 RAs was associated with a 30.5% increase in the prevalence of increased residual gastric contents. This finding indicate that current fasting guidelines may be insufficient for patients on GLP-1 RAs, thereby increasing their aspiration risk [<a href="#b19-dmj-2025-0242" class="usa-link" aria-describedby="b19-dmj-2025-0242">19</a>]. A retrospective cohort study using the TriNetX dataset revealed a significant correlation between GLP-1 RAs use and elevated aspiration pneumonia risk in patients undergoing gastrointestinal endoscopy, particularly among those receiving propofol sedation [<a href="#b20-dmj-2025-0242" class="usa-link" aria-describedby="b20-dmj-2025-0242">20</a>]. However, a recent retrospective cohort study using a nationwide commercial administrative claims database— including 6,806,046 patients with T2DM who underwent outpatient upper endoscopy from 2005 to 2021—reported contrasting findings. It showed that the relative risks for aspiration, aspiration pneumonia, pneumonia, or respiratory failure were not elevated in patients prescribed GLP-1 RA compared to those receiving dipeptidylpeptidase-4 (DPP-4) inhibitors [<a href="#b21-dmj-2025-0242" class="usa-link" aria-describedby="b21-dmj-2025-0242">21</a>]. A comprehensive analysis of 43,365 individuals from two US healthcare databases indicated that GLP-1 RAs do not elevate the risk of pulmonary aspiration during upper gastrointestinal endoscopy in patients with T2DM when compared to SGLT-2 inhibitors, yielding a pooled risk ratio of 0.98 (95% CI, 0.73 to 1.31) among GLP-1 RA users. However, these agents were linked to an increased likelihood of procedure discontinuation, presumably due to aggravated gastric retention [<a href="#b22-dmj-2025-0242" class="usa-link" aria-describedby="b22-dmj-2025-0242">22</a>].</p></section></section><section id="sec8"><h3 class="pmc_sec_title">Mechanism</h3>
<p>Gastric emptying results from a sophisticated interaction between gastric pacemaker cells, gastrointestinal smooth muscle dynamics, and neurohormonal regulatory mechanisms. Both animal and human studies have shown that increased GLP-1 activity reduces intestinal motility [<a href="#b23-dmj-2025-0242" class="usa-link" aria-describedby="b23-dmj-2025-0242">23</a>]. GLP-1 inhibits intestinal contractions through mechanisms that may involve the central nervous system via vagal pathways or direct action on central receptors [<a href="#b24-dmj-2025-0242" class="usa-link" aria-describedby="b24-dmj-2025-0242">24</a>], as well as the enteric nervous system by modulating neurotransmission through presynaptic receptors affecting nitric oxide release [<a href="#b25-dmj-2025-0242" class="usa-link" aria-describedby="b25-dmj-2025-0242">25</a>,<a href="#b26-dmj-2025-0242" class="usa-link" aria-describedby="b26-dmj-2025-0242">26</a>]. This may be further pronounced in patients with diabetes with compromised gastrointestinal function due to autonomic neuropathy. More comprehensive insight into the effects of GLP-1 RAs on gastrointestinal and central nervous system functions is required.</p></section><section id="sec9"><h3 class="pmc_sec_title">Clinical implication</h3>
<p>Considering the potential for gastric food retention and aspiration risks associated with surgical or endoscopic interventions, the American Society of Anesthesiologists recommends the discontinuation of short-acting GLP-1 RAs one day and long-acting formulations at least 1 week before surgical procedures [<a href="#b27-dmj-2025-0242" class="usa-link" aria-describedby="b27-dmj-2025-0242">27</a>]. However, insufficient evidence exists to justify the discontinuation of GLP-1 RAs before the procedure, and the ideal cessation timing for these agents remains indeterminate. A recent cross-sectional study involving 124 participants indicated that 56% of patients still exhibited elevated residual gastric contents despite halting incretin agonists for a minimum of 7 days, thus challenging the practice of discontinuing long-acting GLP-1 RAs solely for this duration prior to surgery [<a href="#b19-dmj-2025-0242" class="usa-link" aria-describedby="b19-dmj-2025-0242">19</a>]. Postponing GLP-1 RAs before endoscopic intervention or surgery may hinder diabetes management and increase cancellation rates without significant advantages. Consequently, the 2024 American Gastroenterology Association (AGA) Rapid Clinical Practice Update recommends that management should depend on upper gastrointestinal symptoms. An 8-hour fast from solids and a 2-hour fast from liquids for individuals on GLP-1 RAs is considered sufficient in the absence of such symptoms [<a href="#b28-dmj-2025-0242" class="usa-link" aria-describedby="b28-dmj-2025-0242">28</a>]. Although data are lacking to justify the cessation of GLP-1 RAs therapy preoperatively, additional precautions should be taken due to aspiration risk. Thus, if gastrointestinal symptoms exist, assessing gastric emptying through solid tests or employing gastric ultrasound to detect retained contents may be warranted.</p></section></section><section id="sec10"><h2 class="pmc_sec_title">HEPATOBILIARY ADVERSE EFFECTS</h2>
<section id="sec11"><h3 class="pmc_sec_title">Evidence based on recent studies</h3>
<p>Several RCTs have demonstrated a significantly higher prevalence of gallbladder disorders among patients treated with GLP-1 RAs compared to placebo [<a href="#b29-dmj-2025-0242" class="usa-link" aria-describedby="b29-dmj-2025-0242">29</a>-<a href="#b32-dmj-2025-0242" class="usa-link" aria-describedby="b32-dmj-2025-0242">32</a>], as initially evidenced by the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, which reported acute gallstone disease rates of 3.1% in the liraglutide group versus 1.9% in the placebo cohort (<em>P</em>&lt;0.001) [<a href="#b33-dmj-2025-0242" class="usa-link" aria-describedby="b33-dmj-2025-0242">33</a>]. <em>Post hoc</em> analysis of LEADER data revealed a persistent increase in the overall risk of biliary tract-related events and gallbladder diseases, consistently observed across four categories: uncomplicated gallbladder stones, complicated gallbladder stones, cholecystitis with/without gallbladder stones, and biliary obstruction [<a href="#b34-dmj-2025-0242" class="usa-link" aria-describedby="b34-dmj-2025-0242">34</a>]. Faillie et al. [<a href="#b35-dmj-2025-0242" class="usa-link" aria-describedby="b35-dmj-2025-0242">35</a>] conducted the first population-based study linked the UK CPRD with the Hospital Episodes Statistics database, examining the relationship between incretin-based medications and the incidence of hospitalization due to bile duct and gallbladder diseases. They found that current DPP-4 inhibitor usage did not correlate with an increased risk of these conditions compared to at least two oral antidiabetic drugs predominantly comprising metformin and sulfonylurea (3.6 vs. 3.3 per 1,000 person-years; adjusted HR, 0.99; 95% CI, 0.75 to 1.32), whereas the use of GLP-1 analogues was linked to an increased risk (6.1 vs. 3.3 per 1,000 person-years; adjusted HR, 1.79; 95% CI, 1.21 to 2.67) [<a href="#b35-dmj-2025-0242" class="usa-link" aria-describedby="b35-dmj-2025-0242">35</a>]. Extending the findings from the UK cohort study, additional real-world data derived from the Taiwan National Health Insurance Database—which encompasses Asian populations characterized by lower gallstone prevalence, low-fat and high-fiber dietary patterns, and lower body mass index—also documented an elevated risk of biliary-related diseases linked to GLP-1 RAs compared with SGLT-2 inhibitors [<a href="#b36-dmj-2025-0242" class="usa-link" aria-describedby="b36-dmj-2025-0242">36</a>]. In that study, liraglutide (HR, 1.33; 95% CI, 1.00 to 1.77) exhibited a significantly elevated risk, whereas dulaglutide did not. Liraglutide has a significantly lower molecular weight than dulaglutide (3.8 kDa albumin binding heptamer vs. 59.7 kDa immunoglobulin G4-fusion molecule), a shorter half-life (11–15 hours vs. 5 days), is partially metabolized and excreted via the biliary route, and exerts a stronger weight-reducing effect; these factors may contribute to a higher incidence of hepatobiliary adverse events [<a href="#b2-dmj-2025-0242" class="usa-link" aria-describedby="b2-dmj-2025-0242">2</a>,<a href="#b37-dmj-2025-0242" class="usa-link" aria-describedby="b37-dmj-2025-0242">37</a>]. The differential impact of various GLP-1 RAs on biliary disorders remains ambiguous; nonetheless, the Researching cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial indicated no significant hepatobiliary adverse events in the dulaglutide cohort vs. placebo (2.4% vs. 2.1%, P=0.450) [<a href="#b38-dmj-2025-0242" class="usa-link" aria-describedby="b38-dmj-2025-0242">38</a>]. Additional research is required to ascertain the variability in the risk of biliary diseases associated with GLP-1 RAs. A recent systematic review and meta-analysis encompassing 76 RCTs demonstrated that GLP-1 RA therapy considerably elevated the probability of gallbladder and biliary disorders (pooled relative risk, 1.37; 95% CI, 1.23 to 1.52) [<a href="#b39-dmj-2025-0242" class="usa-link" aria-describedby="b39-dmj-2025-0242">39</a>]. This augmented risk was particularly pronounced in the context of weight loss interventions compared to diabetes management (<em>P</em> for interaction &lt;0.001), when using higher rather than lower dosages (<em>P</em> for interaction=0.006), and with extended treatment duration compared to shorter intervals (<em>P</em> for interaction=0.030).</p></section><section id="sec12"><h3 class="pmc_sec_title">Mechanism</h3>
<p>Although the biological rationale for GLP-1 RA-induced biliary toxicity is not clear, the current findings indicate potential weight-loss-dependent mechanisms. Cholelithiasis is a common complication associated with weight reduction interventions, with the incidence of new gallstone formation exceeding 30% after gastric bypass surgery in obese populations [<a href="#b40-dmj-2025-0242" class="usa-link" aria-describedby="b40-dmj-2025-0242">40</a>]. Weight reduction results in cholesterol supersaturation in the bile, thereby increasing the risk of gallstone formation [<a href="#b40-dmj-2025-0242" class="usa-link" aria-describedby="b40-dmj-2025-0242">40</a>]. Another pathway contribute to gallbladder-related complications independently of weight reduction. GLP-1 hinders gallbladder motility and postpones gallbladder evacuation by inhibiting cholecystokinin secretion [<a href="#b40-dmj-2025-0242" class="usa-link" aria-describedby="b40-dmj-2025-0242">40</a>-<a href="#b44-dmj-2025-0242" class="usa-link" aria-describedby="b44-dmj-2025-0242">44</a>]. Small-scale clinical trials have reported that exenatide and liraglutide can diminish gallbladder emptying or extend the time to reach the peak postprandial gallbladder ejection fraction [<a href="#b42-dmj-2025-0242" class="usa-link" aria-describedby="b42-dmj-2025-0242">42</a>,<a href="#b45-dmj-2025-0242" class="usa-link" aria-describedby="b45-dmj-2025-0242">45</a>]. Compounded gallbladder motility results in sludge accumulation and gallstone development [<a href="#b46-dmj-2025-0242" class="usa-link" aria-describedby="b46-dmj-2025-0242">46</a>]. Further, direct stimulation of the GLP-1 receptor on cholangiocytes can lead to enhanced cellular proliferation and an elevated likelihood of cholestasis [<a href="#b47-dmj-2025-0242" class="usa-link" aria-describedby="b47-dmj-2025-0242">47</a>]. Experimental investigations have demonstrated that cholangiocytes are sensitive to GLP-1 and respond with augmented proliferation, potentially increasing the risk of duct obstruction [<a href="#b47-dmj-2025-0242" class="usa-link" aria-describedby="b47-dmj-2025-0242">47</a>,<a href="#b48-dmj-2025-0242" class="usa-link" aria-describedby="b48-dmj-2025-0242">48</a>].</p></section><section id="sec13"><h3 class="pmc_sec_title">Clinical implication</h3>
<p>Although the association between GLP-1 RAs and gallbladder/biliary diseases has been supported by multiple studies, causality has not been definitively established. To reduce these potential risks, healthcare providers are advised to closely monitor patients, particularly those with a history of gallbladder or biliary disease [<a href="#b49-dmj-2025-0242" class="usa-link" aria-describedby="b49-dmj-2025-0242">49</a>].</p></section></section><section id="sec14"><h2 class="pmc_sec_title">PANCREAS ADVERSE EFFECTS</h2>
<section id="sec15"><h3 class="pmc_sec_title">Evidence based on recent studies</h3>
<p>Acute pancreatitis following exenatide administration has been documented in case reports since 2006 [<a href="#b50-dmj-2025-0242" class="usa-link" aria-describedby="b50-dmj-2025-0242">50</a>]. This concern was further highlighted by an analysis of the US FDA adverse events database. From 2004 to 2009, an analysis of the database revealed a six-fold increase in pancreatitis incidents linked to the DPP-4 inhibitor sitagliptin and the GLP-1 mimetic exenatide, the first two GLP-1-based medications marketed in the US [<a href="#b51-dmj-2025-0242" class="usa-link" aria-describedby="b51-dmj-2025-0242">51</a>]. In that report, the incidence of pancreatic cancer was also 2.9 and 2.7 times greater with exenatide and sitagliptin, respectively, compared to other oral antidiabetic medications. A recent analysis of FDA adverse event reporting system (FAERS) data from 2004 to 2020 revealed a notable association between GLP-1 RAs and malignant pancreatic neoplasms (proportional reporting ratio [PRR], 9.86) [<a href="#b52-dmj-2025-0242" class="usa-link" aria-describedby="b52-dmj-2025-0242">52</a>]. Although the FAERS database aids in detecting rare adverse events via spontaneous reporting, its propensity to overestimate unexpected adverse events linked to new therapies makes it inappropriate for comparative analysis of adverse event frequencies among pharmaceuticals.</p>
<p>Initial concerns regarding the possible link between the use of GLP-1 RAs and the development of pancreatitis or pancreatic cancer have not been supported by the results of RCTs [<a href="#b53-dmj-2025-0242" class="usa-link" aria-describedby="b53-dmj-2025-0242">53</a>,<a href="#b54-dmj-2025-0242" class="usa-link" aria-describedby="b54-dmj-2025-0242">54</a>], or real-world data [<a href="#b29-dmj-2025-0242" class="usa-link" aria-describedby="b29-dmj-2025-0242">29</a>,<a href="#b55-dmj-2025-0242" class="usa-link" aria-describedby="b55-dmj-2025-0242">55</a>,<a href="#b56-dmj-2025-0242" class="usa-link" aria-describedby="b56-dmj-2025-0242">56</a>]. Most RCTs failed to demonstrate a significant association between GLP-1 RAs and the occurrence of pancreatitis or pancreatic cancer, primarily because of their short duration and insufficient design for evaluating such risks. Based on an analysis of 68 RCTs encompassing 60,720 participants, Shihab et al. [<a href="#b57-dmj-2025-0242" class="usa-link" aria-describedby="b57-dmj-2025-0242">57</a>] demonstrated that GLP-1 based agents were associated with a three-fold increased risk of pancreatic enzyme elevation relative to controls, yet did not indicate a significant rise in pancreatitis or pancreatic cancer. A meta-analysis of 113 RCTs comprising 33,167 patients in the GLP-1 RA cohort and 26,683 in the comparator cohort revealed no significant elevation in pancreatitis or pancreatic cancer risk relative to control groups (Mantel-Haenszel odds ratio [MH-OR] of 0.93 and 0.94, respectively), but identified a notable increase in cholelithiasis risk (MH-OR, 1.30) [<a href="#b58-dmj-2025-0242" class="usa-link" aria-describedby="b58-dmj-2025-0242">58</a>]. A recent meta-analysis of 11 cardiovascular outcome trials involving 55,921 patients treated with GLP-1 RAs and 43,306 patients treated with DPP-4 inhibitors also revealed no significant association between either drug class and pancreatic cancer risk. However, while GLP-1 RAs did not exhibit an increased risk of acute pancreatitis, DPP-4 inhibitors demonstrated a notable risk elevation (rate ratio, 1.75) [<a href="#b53-dmj-2025-0242" class="usa-link" aria-describedby="b53-dmj-2025-0242">53</a>]. It is important to note that randomized trials typically involve a highly selective group of individuals who do not accurately reflect the general population with T2DM. For instance, clinical trials on pancreatitis rarely include individuals with a history of heavy alcohol consumption. Therefore, if GLP-1 RA treatment specifically increases the risk of pancreatitis in this vulnerable population, such an effect would likely remain undetected in randomized trials.</p>
<p>In contrast to RCTs, retrospective observational studies offer the benefit of capturing extensive patient data in real-world settings. In a comprehensive US administrative database from 2005 to 2008, GLP-1-based treatments, particularly sitagliptin and exenatide, were associated with a significantly increased risk of acute pancreatitis-related hospitalization in adults with T2DM [<a href="#b59-dmj-2025-0242" class="usa-link" aria-describedby="b59-dmj-2025-0242">59</a>], thereby reinforcing prior mechanistic experimental studies and spontaneous reports to the FDA suggesting a potential causal relationship. Nonetheless, investigators from the Canadian Network for Observational Drug Effect Studies (CNODES) reported contradictory results. They concluded that incretin-based medications did not correlate with an increased risk of acute pancreatitis or pancreatic cancer compared to other oral anti-diabetic agents, which remained consistent across drug classification and duration of use [<a href="#b29-dmj-2025-0242" class="usa-link" aria-describedby="b29-dmj-2025-0242">29</a>,<a href="#b55-dmj-2025-0242" class="usa-link" aria-describedby="b55-dmj-2025-0242">55</a>]. Furthermore, a recent extensive cohort study involving over 33,000 GLP-1 RA users diagnosed with diabetes over a 9-year period indicated no significant increase in pancreatic cancer risk associated with GLP-1 RA use, as evidenced by an HR of 0.50 compared to basal insulin [<a href="#b60-dmj-2025-0242" class="usa-link" aria-describedby="b60-dmj-2025-0242">60</a>]. In the Veterans Health Administration (VHA) national dataset, an adjusted OR indicated no significant difference in pancreatitis occurrences between thiazolidinedione and incretin groups (adjusted OR, 0.94; 95% CI, 0.75 to 1.18) [<a href="#b56-dmj-2025-0242" class="usa-link" aria-describedby="b56-dmj-2025-0242">56</a>]. Despite the limitations of real-world observational studies—including the absence of randomization, control for confounding variables, and inability to establish causality—researches offer confidence regarding the pancreatic safety profiles of GLP-1 RAs [<a href="#b55-dmj-2025-0242" class="usa-link" aria-describedby="b55-dmj-2025-0242">55</a>,<a href="#b61-dmj-2025-0242" class="usa-link" aria-describedby="b61-dmj-2025-0242">61</a>].</p></section><section id="sec16"><h3 class="pmc_sec_title">Mechanism</h3>
<p>In response to a previous FDA inquiry, two short-term mechanical studies were conducted using exenatide and liraglutide in a diabetic rat model, wherein one rat administered with exenatide died of pancreatic necrosis, while the others exhibited acinar-to-ductal metaplasia and ductal hyperplasia, indicative of potential premalignant alterations [<a href="#b62-dmj-2025-0242" class="usa-link" aria-describedby="b62-dmj-2025-0242">62</a>,<a href="#b63-dmj-2025-0242" class="usa-link" aria-describedby="b63-dmj-2025-0242">63</a>]. Persistent activation of GLP-1 receptors in exocrine pancreatic cells may lead to localized hyperplasia in the exocrine pancreas, consequently accelerating the formation of dysplastic lesions and pancreatitis [<a href="#b64-dmj-2025-0242" class="usa-link" aria-describedby="b64-dmj-2025-0242">64</a>]. Although experimental studies suggest potential pancreatic harm from GLP-1 RAs, robust clinical evidence demonstrates that these drugs do not increase the incidence of pancreatitis or pancreatic cancer in diverse human populations. This contrasts with controlled animal model findings, which may not accurately reflect real-world complexities.</p></section><section id="sec17"><h3 class="pmc_sec_title">Clinical implication</h3>
<p>Clinicians are encouraged to perform comprehensive evaluations prior to prescribing GLP-1 RA therapy in patients with a history of pancreatic disorders or other pancreatitis risk factors. However, past pancreatitis is not a contraindication for these agents, and contrary to the previous warning, recent studies have not shown an increased pancreatic risk associated with GLP-1 RAs, leading to ongoing revisions in treatment guidelines. In cases where pancreatitis is suspected, discontinuation of GLP-1 RA and appropriate medical intervention are recommended according to the risks and benefits for each patient [<a href="#b65-dmj-2025-0242" class="usa-link" aria-describedby="b65-dmj-2025-0242">65</a>].</p></section></section><section id="sec18"><h2 class="pmc_sec_title">PSYCHIATRIC ADVERSE EFFECTS</h2>
<section id="sec19"><h3 class="pmc_sec_title">Evidence based on recent studies</h3>
<p>The prevalence of various neuropsychiatric disorders is high in individuals with obesity [<a href="#b66-dmj-2025-0242" class="usa-link" aria-describedby="b66-dmj-2025-0242">66</a>]. Suicidal ideation is associated with the use of various weight reduction drugs [<a href="#b67-dmj-2025-0242" class="usa-link" aria-describedby="b67-dmj-2025-0242">67</a>,<a href="#b68-dmj-2025-0242" class="usa-link" aria-describedby="b68-dmj-2025-0242">68</a>]. Certain anti-obesity drugs, including selective serotonin reuptake inhibitors and naltrexone/bupropion combinations, have been linked to adverse psychological outcomes such as mood alterations and suicidal ideation [<a href="#b69-dmj-2025-0242" class="usa-link" aria-describedby="b69-dmj-2025-0242">69</a>]. Furthermore, the EMA has withdrawn the weight loss medication rimonabant, a selective cannabinoid type 1 receptor antagonist, due to its reported links to increased risks of depression and suicide [<a href="#b70-dmj-2025-0242" class="usa-link" aria-describedby="b70-dmj-2025-0242">70</a>].</p>
<p>In 2017, a <em>post hoc</em> pooled analysis of RCTs on liraglutide demonstrated comparably low incidences of depression and anxiety in both the liraglutide and placebo cohorts. However, a slight numerical increase in suicidal ideation was observed among liraglutide recipients, with nine cases (0.3%) in the liraglutide group compared to two cases (0.1%) in the placebo group [<a href="#b71-dmj-2025-0242" class="usa-link" aria-describedby="b71-dmj-2025-0242">71</a>]. In July 2023, the EMA initiated an inquiry into safety concerns after receiving approximately 150 spontaneous reports indicating potential links between drugs and suicide ideation or self-harm [<a href="#b72-dmj-2025-0242" class="usa-link" aria-describedby="b72-dmj-2025-0242">72</a>]. The WHO’s VigiBase identified a notable disproportionality signal for suicidal ideation linked to semaglutide (reported odds ratio [ROR], 1.45; 95% CI, 1.18 to 1.77), absent for liraglutide, especially in patients concurrently using antidepressants (ROR, 4.45; 95% CI, 2.52 to 7.86) [<a href="#b73-dmj-2025-0242" class="usa-link" aria-describedby="b73-dmj-2025-0242">73</a>]. McIntyre et al. [<a href="#b74-dmj-2025-0242" class="usa-link" aria-describedby="b74-dmj-2025-0242">74</a>] analyzed the FAERS data from 2005 to October 2023, revealing a notable incidence of suicidal ideation and depression linked to semaglutide and liraglutide, with no recorded cases of suicidal behaviors or completed suicides. The primary limitation of FAERS is its dependence on voluntary adverse event reporting, which restricts its ability to comprehensively document all occurrences. However, the recent heightened social media attention on GLP-1 RAs, notably semaglutide and liraglutide, may have resulted in an imbalanced surge in reporting relative to other pharmaceuticals.</p>
<p>RCTs evaluating GLP-1 RA have not identified indicators of suicidality. The <em>post hoc</em> analysis of pooled data from the Semaglutide Treatment Effect in People with Obesity (STEP) 1, 2, 3, and 5 trials indicated that semaglutide treatment at 2.4 mg did not increase the risk of depressive symptoms or suicidal ideation compared to placebo, while demonstrating a statistically significant yet clinically negligible decrease in depressive symptoms [<a href="#b75-dmj-2025-0242" class="usa-link" aria-describedby="b75-dmj-2025-0242">75</a>]. Nonetheless, these clinical trials were underpowered to detect rare events such as suicidal ideation and self-injurious behavior, and they systematically excluded patients with psychiatric comorbidities commonly seen in clinical settings.</p>
<p>Retrospective cohort studies using real-world data have indicated a neutral or reduced impact of GLP-1 RAs on suicidal ideation. Hurtado et al. [<a href="#b76-dmj-2025-0242" class="usa-link" aria-describedby="b76-dmj-2025-0242">76</a>] found no evidence of increased risk of suicidal ideation and self-injury associated with GLP-1 RAs compared to SGLT-2 inhibitors in individuals with T2DM and obesity, based on data from the Valencia Health System Integrated Database (VID) (per-protocol analysis: HR, 1.04; 95% CI, 0.35 to 3.14). Nationwide retrospective studies utilizing register data from Sweden and Denmark (2013–2021) and the UK CPRD (2007–2020) have revealed consistent findings, indicating that GLP-1 RAs are not associated with an elevated risk of suicidality relative to DPP-4 or SGLT-2 inhibitors [<a href="#b77-dmj-2025-0242" class="usa-link" aria-describedby="b77-dmj-2025-0242">77</a>,<a href="#b78-dmj-2025-0242" class="usa-link" aria-describedby="b78-dmj-2025-0242">78</a>]. A recent meta-analysis encompassing 11 observational and case-control studies across various countries revealed no statistically significant disparity in suicidal outcomes between GLP-1 RA users and those utilizing alternative antihyperglycemic medications (relative risk, 0.57; 95% CI, 0.08 to 4.21) [<a href="#b79-dmj-2025-0242" class="usa-link" aria-describedby="b79-dmj-2025-0242">79</a>]. On the other hand, in the retrospective cohort study using TriNetX Analytics Network electronic health records, semaglutide significantly lowered the risk of both new (HR, 0.27; 95% CI, 0.20 to 0.32) and recurrent (HR, 0.44; 95% CI, 0.32 to 0.60) suicidal ideation compared to non-GLP-1 RAs anti-obesity treatments [<a href="#b80-dmj-2025-0242" class="usa-link" aria-describedby="b80-dmj-2025-0242">80</a>]. However, the limited follow-up duration of 6 months raised concerns about potential reverse causality, as undetected suicidal ideation and medical conditions might have influenced the choice of particular anti-obesity or anti-diabetic drugs. Furthermore, such a retrospective design inherently limits the identification of causal relationships, and unmeasured residual confounding variables—such as glycemic control, hypoglycemic episodes, familial suicide history, and socioeconomic status—may persist. Therefore, given the rarity of suicidal or self-harming behaviors, the limited sample size of the RCT, and the inherent limitations of retrospective studies, comprehensive research with long-term follow-up and rigorous mental health assessments is needed to clarify the potential risks and benefits.</p></section><section id="sec20"><h3 class="pmc_sec_title">Mechanism</h3>
<p>The precise mechanisms underlying these adverse psychiatric effects remain unclear. The interplay between obesity, weight loss, anti-obesity medication, and suicidal ideation is complex. The timing of suicidal ideation in relation to ongoing drug administration or cessation remains unclear. Sudden weight reduction or maladaptation to an altered body perception may elicit biological and psychological reactions that can potentially impact suicidal thoughts. GLP-1 receptors are distributed in multiple brain regions implicated in mood regulation, such as the hypothalamus, hippocampus, amygdala, and pancreas. This suggests that GLP-1 RAs may directly influence these areas, thereby affecting emotional and behavioral states [<a href="#b81-dmj-2025-0242" class="usa-link" aria-describedby="b81-dmj-2025-0242">81</a>]. Moreover, GLP-1 receptors interact with various neurotransmitter systems such as serotonin, dopamine, and glutamate, which are essential for mood regulation and may contribute to the onset of depression and other psychological disorders [<a href="#b82-dmj-2025-0242" class="usa-link" aria-describedby="b82-dmj-2025-0242">82</a>]. The role of GLP-1 in the nervous system remains inconclusive, yet indicates its potential for alleviating neuroinflammation, safeguarding neurons and glial cells from oxidative damage, and optimizing neurotransmitter equilibrium [<a href="#b83-dmj-2025-0242" class="usa-link" aria-describedby="b83-dmj-2025-0242">83</a>]. GLP-1 RAs not only ameliorate insulin resistance and microvascular injury [<a href="#b84-dmj-2025-0242" class="usa-link" aria-describedby="b84-dmj-2025-0242">84</a>], which are significant determinants of depression in T2DM, but also enhance dopamine metabolism and stimulate growth factor signaling pathways, suggesting potential neuroprotective functions [<a href="#b85-dmj-2025-0242" class="usa-link" aria-describedby="b85-dmj-2025-0242">85</a>,<a href="#b86-dmj-2025-0242" class="usa-link" aria-describedby="b86-dmj-2025-0242">86</a>]. Further studies are required to clarify the complex interactions between GLP-1 RAs and various neuropsychiatric processes.</p></section><section id="sec21"><h3 class="pmc_sec_title">Clinical implication</h3>
<p>The updated FDA labeling for liraglutide and semaglutide highlights the importance of monitoring depressive symptoms or suicidal thoughts, suggesting treatment discontinuation if such ideations occur [<a href="#b87-dmj-2025-0242" class="usa-link" aria-describedby="b87-dmj-2025-0242">87</a>,<a href="#b88-dmj-2025-0242" class="usa-link" aria-describedby="b88-dmj-2025-0242">88</a>]. However, current evidence does not strongly justify the cessation of GLP-1 RAs based on suicidality concerns. Consequently, it is essential to prioritize shared decision-making and individualized risk-benefit assessments for prescribing GLP-1 RAs, while avoiding misuse with off-label indications.</p></section></section><section id="sec22"><h2 class="pmc_sec_title">OCULAR ADVERSE EFFECTS</h2>
<section id="sec23"><h3 class="pmc_sec_title">Evidence based on recent studies</h3>
<p>While GLP-1 RAs have demonstrated potent glucose-lowering effects, their impact on diabetic retinopathy remains incompletely elucidated. In 2016, concerns regarding retinopathy associated with GLP-1 were first raised in the Semaglutide Unabated Sustainability in Treatment of T2DM (SUSTAIN) 6 trial with semaglutide [<a href="#b89-dmj-2025-0242" class="usa-link" aria-describedby="b89-dmj-2025-0242">89</a>]. Patients receiving semaglutide (0.5 or 1.0 mg) for 104 weeks demonstrated a significantly higher risk of diabetic retinopathy complications, including vitreous hemorrhage, blindness, or required procedural treatment compared to those receiving placebo (HR, 1.76; 95% CI, 1.11 to 2.78). Similarly, the LEADER trial with liraglutide showed a numerically higher, though non-significant, rate of diabetic retinopathy events compared to placebo (HR, 1.15; 95% CI, 0.87 to 1.52) [<a href="#b33-dmj-2025-0242" class="usa-link" aria-describedby="b33-dmj-2025-0242">33</a>]. The REWIND cardiovascular outcome trial also revealed that dulaglutide administration resulted in inferior ocular outcomes, leading to an increased need for interventions such as photocoagulation, anti-vascular endothelial growth factor (VEGF) therapy, or vitrectomy compared to placebo recipients [<a href="#b38-dmj-2025-0242" class="usa-link" aria-describedby="b38-dmj-2025-0242">38</a>]. As a result, a meta-analysis of 13 RCTs revealed that GLP-1 RAs, including liraglutide, semaglutide, and dulaglutide, are associated with a 23% increased risk of rapid worsening of diabetic retinopathy in T2DM (OR, 1.23; 95% CI 1.05 to 1.44), with longer treatment periods associated with a greater risk [<a href="#b90-dmj-2025-0242" class="usa-link" aria-describedby="b90-dmj-2025-0242">90</a>]. However, these trials concentrated on cardiovascular outcomes rather than ocular ones, with inconsistent definitions and grading, rendering them insufficient for evaluating the long-term stabilization or enhancement of retinal pathology following an acute reduction in glycosylated hemoglobin (HbA1c). <em>Post hoc</em> evaluations of the SUSTAIN 6 trial revealed that semaglutide markedly increased the incidence of diabetic retinopathy complications in individuals with a history of retinopathy, especially among insulin users, presumably due to the swift deterioration of pre-existing retinopathy following rapid glycemic control [<a href="#b91-dmj-2025-0242" class="usa-link" aria-describedby="b91-dmj-2025-0242">91</a>]. Similarly, a meta-analysis of six placebo-controlled trials indicated that the worsening of diabetic retinopathy correlated with reductions in average HbA1c rather than with GLP-1 RA treatment [<a href="#b92-dmj-2025-0242" class="usa-link" aria-describedby="b92-dmj-2025-0242">92</a>].</p>
<p>Real-world studies have shown heterogeneous findings. A retrospective cohort studies using the TriNeX database found that GLP-1 RA therapy combined with insulin was associated with a higher risk of diabetic retinopathy (HR, 1.21; 95% CI, 1.15 to 1.26) and diabetic macular edema (HR, 1.13; 95% CI, 1.06 to 1.21) compared to SGLT-2 inhibitor therapy with insulin [<a href="#b93-dmj-2025-0242" class="usa-link" aria-describedby="b93-dmj-2025-0242">93</a>]. Conversely, a retrospective study with 981 patients with T2DM showed no difference in diabetic retinopathy progression between GLP-1 RAs and SGLT-2 inhibitors [<a href="#b94-dmj-2025-0242" class="usa-link" aria-describedby="b94-dmj-2025-0242">94</a>]. Analysis of FAERS data from 2003 to 2024 showed significant associations between diabetic retinopathy and semaglutide (PRR, 19.43), dulaglutide (PRR, 9.01), and liraglutide (PRR, 4.4) [<a href="#b95-dmj-2025-0242" class="usa-link" aria-describedby="b95-dmj-2025-0242">95</a>].</p>
<p>Non-arteritic anterior ischemic optic neuropathy (NAION) is characterized by optic nerve ischemia leading to abrupt vision loss, yet its pathophysiology remains inadequately understood [<a href="#b96-dmj-2025-0242" class="usa-link" aria-describedby="b96-dmj-2025-0242">96</a>]. In 2024, Hathaway et al. [<a href="#b97-dmj-2025-0242" class="usa-link" aria-describedby="b97-dmj-2025-0242">97</a>] observed a potential association between semaglutide and NAION, with incidence rates of 4.28 and 7.64 per 1,000 person-years in patients with T2DM and those who were overweight or obese, respectively, over 36 months. The FAERS database also revealed 41 reported cases for semaglutide with an ROR of 11.36 (95% CI, 8.33 to 15.49) and a PRR of 11.36 (95% CI, 8.32 to 15.47), suggesting a potential causal relationship between semaglutide and NAION [<a href="#b98-dmj-2025-0242" class="usa-link" aria-describedby="b98-dmj-2025-0242">98</a>]. However, Abbas et al. [<a href="#b99-dmj-2025-0242" class="usa-link" aria-describedby="b99-dmj-2025-0242">99</a>] showed different results using a retrospective matched cohort study that utilized the TriNetX, found no increased risk of NAION or ischemic optic neuropathy among patients with T2DM or elevated BMI prescribed semaglutide over 5 years. Because these findings are based on limited, recently published datasets with conflicting results, ongoing pharmacovigilance and large-scale prospective studies are needed.</p></section><section id="sec24"><h3 class="pmc_sec_title">Mechanism</h3>
<p>Although the exact mechanisms underlying GLP-1 RA-induced diabetic retinopathy remain unclear, several hypotheses have been proposed. The early deterioration of diabetic retinopathy observed with GLP-1 RAs may reflect rapid glucose decline that affects osmotic pressure rather than direct retinal toxicity [<a href="#b91-dmj-2025-0242" class="usa-link" aria-describedby="b91-dmj-2025-0242">91</a>]. This rapid glucose lowering can also induce hypoxia, which may modulate the effect of GLP-1 RAs on retinal VEGF expression [<a href="#b100-dmj-2025-0242" class="usa-link" aria-describedby="b100-dmj-2025-0242">100</a>]. Additionally, GLP-1 has been shown to enhance the proliferation and differentiation of endothelial progenitor cells through upregulation of VEGF, potentially promoting angiogenesis that could contribute to retinal complications [<a href="#b101-dmj-2025-0242" class="usa-link" aria-describedby="b101-dmj-2025-0242">101</a>,<a href="#b102-dmj-2025-0242" class="usa-link" aria-describedby="b102-dmj-2025-0242">102</a>].</p>
<p>However, GLP-1 RAs may also confer neuroprotective benefits to the retina. Recent studies have demonstrated abundant GLP-1 receptors in human retinal tissue, suggesting potential for direct neuroprotective effects [<a href="#b103-dmj-2025-0242" class="usa-link" aria-describedby="b103-dmj-2025-0242">103</a>]. GLP-1 RAs may inhibit retinal neurodegeneration and reduce proinflammatory processes, which could protect against diabetic retinopathy progression.</p>
<p>While the precise mechanism of NAION remains unknown, the effects of GLP-1 on vascular function, glucose homeostasis, and neuroprotection may potentially influence NAION development. The mechanisms of GLP-1 RAs’ action in retinopathy and NAION remain incompletely understood, highlighting the need for large trials with baseline retinal grading and extended follow-up. The ongoing dedicated ophthalmic trial named as FOCUS study, which aims to evaluate semaglutide’s long-term effects on diabetic retinopathy, is now ongoing and could contribute to a comprehensive understanding of the true risk-benefit profile of these agents in patients with or at risk for diabetic retinopathy (<a href="https://clinicaltrials.gov/ct2/show/NCT03811561" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT03811561</a>) [<a href="#b104-dmj-2025-0242" class="usa-link" aria-describedby="b104-dmj-2025-0242">104</a>].</p></section><section id="sec25"><h3 class="pmc_sec_title">Clinical implication</h3>
<p>The potential ocular complications associated with GLP-1 RAs need careful clinical consideration. However, due to discrepancies in findings from clinical trials, real-world data, and fundamental research, definitive recommendations for diabetic retinopathy screening prior to GLP-1 RA treatment initiation remain elusive. Instead, clinicians should acknowledge this risk and consider individualized risk-benefit strategies when prescribing GLP-1 RAs, particularly for patients with pre-existing ocular manifestations and must inform patients regarding possible ocular hazards while advocating for regular retinal examinations and assessments of visual acuity.</p></section></section><section id="sec26"><h2 class="pmc_sec_title">OTHERS</h2>
<section id="sec27"><h3 class="pmc_sec_title">Other cancers</h3>
<p>Recent investigations have highlighted the association between various neoplasms, such as thyroid, breast, and cholangiocarcinoma, and GLP-1 RAs [<a href="#b105-dmj-2025-0242" class="usa-link" aria-describedby="b105-dmj-2025-0242">105</a>-<a href="#b107-dmj-2025-0242" class="usa-link" aria-describedby="b107-dmj-2025-0242">107</a>]. Notably, a 2020 clinical trial involving patients with nonalcoholic steatohepatitis (NASH) revealed a 15% incidence of tumors (benign, malignant, or unspecified) (35/239) among those administered semaglutide, compared to 8% (6/80) in the control group [<a href="#b108-dmj-2025-0242" class="usa-link" aria-describedby="b108-dmj-2025-0242">108</a>]. However, to date, extensive RCTs have shown no correlation between specific GLP-1 RAs and increased cancer risk. Participants in RCTs typically comprise relatively healthy individuals, excluding those with a history of medullary thyroid cancer or pancreatitis, and the duration of the RCTs is insufficient to induce cancer. Thus, spontaneous reporting may be the most effective method for identifying infrequent adverse events. Analysis of FAERS data from 2004 to 2020 revealed significant associations between GLP-1 RA and various neoplasms, notably medullary thyroid cancer (PRR, 27.43), papillary thyroid cancer (PRR, 8.68), malignant pancreatic neoplasms (PRR, 9.86), and pancreatic neuroendocrine neoplasms (PRR, 2.86) [<a href="#b52-dmj-2025-0242" class="usa-link" aria-describedby="b52-dmj-2025-0242">52</a>]. The FDA’s prior warnings regarding the potential elevated risk of medullary thyroid carcinoma associated with GLP-1 RAs may encourage more patients on GLP-1 RA therapy to undergo thyroid ultrasounds, thereby enhancing tumor detection. Furthermore, certain spontaneous reports lacked validation from healthcare professionals, and there was an absence of data regarding the patients’ physical conditions, familial history, and individual histories of alcohol and tobacco use, all of which could potentially affect cancer development. Therefore, the results from the FAERS database should be interpreted with caution as they can overestimate adverse events due to reporting bias and do not establish causality. Recently, a comprehensive cohort study utilizing data from the Korean National Health Insurance Service from 2004 to 2021 indicated no significant correlation between GLP-1 RAs and the incidence of new-onset malignancies, with a median follow-up of 8 years [<a href="#b109-dmj-2025-0242" class="usa-link" aria-describedby="b109-dmj-2025-0242">109</a>]. Future research is warranted to explore the prolonged implications of GLP-1 RAs on oncogenic risk. While clinicians should not limit their usage due to cancer concerns, they must maintain a thorough surveillance for possible adverse outcomes.</p></section><section id="sec28"><h3 class="pmc_sec_title">Sarcopenia</h3>
<p>Approximately 40% of the weight reduction associated with GLP-1 RAs is derived from a lean body mass, which raises significant concerns regarding its potential negative impact on skeletal muscle functionality [<a href="#b110-dmj-2025-0242" class="usa-link" aria-describedby="b110-dmj-2025-0242">110</a>]. In the SUSTAIN 8 study, patients with T2DM exhibited a lean mass decrease of 2.3 kg alongside a total weight loss of 5.3 kg, resulting in 43.4% of weight loss attributable to lean mass, while the ratio of lean mass to total mass increased by 1.2% from the baseline [<a href="#b111-dmj-2025-0242" class="usa-link" aria-describedby="b111-dmj-2025-0242">111</a>]. Current evidence, including magnetic resonance imaging studies, suggests that skeletal muscle alterations resulting from GLP-1 RA-induced weight loss, such as enhanced insulin sensitivity and reduced muscle fat infiltration, are adaptive, thereby improving muscle quality despite concurrent reductions in lean mass [<a href="#b112-dmj-2025-0242" class="usa-link" aria-describedby="b112-dmj-2025-0242">112</a>]. Recently, to ensure the safety of GLP-1 RA on sarcopenia, a clinical randomized multicenter trial of bimagrumab, an antibody blockade of activin type II receptor inhibitor, alone or in addition to subcutaneous semaglutide is now ongoing (<a href="https://clinicaltrials.gov/ct2/show/NCT05616013" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">NCT05616013</a>) [<a href="#b113-dmj-2025-0242" class="usa-link" aria-describedby="b113-dmj-2025-0242">113</a>]. While studies in mice indicate the potential direct benefits of GLP-1 on the skeletal muscle and bone, human data supporting this hypothesis are absent owing to the absence of GLP-1 receptors in the human skeletal muscle, implying that any effects on muscles are likely indirect [<a href="#b114-dmj-2025-0242" class="usa-link" aria-describedby="b114-dmj-2025-0242">114</a>]. Future research on GLP-1-based medicines for weight reduction must prioritize the precise evaluation of muscle mass, composition, and functionality to clarify their impact on muscular health.</p></section></section><section id="sec29"><h2 class="pmc_sec_title">CONCLUSIONS</h2>
<p>Recent investigations have elucidated a multifaceted spectrum of adverse effects linked to GLP-1 RAs (<a href="#t1-dmj-2025-0242" class="usa-link">Table 1</a>), necessitating meticulous interpretation based on the various methodological designs employed, including RCTs and retrospective analyses. Notably, although gallbladder disorders frequently manifest, advanced gastrointestinal complications such as intestinal obstruction and periprocedural aspiration, and emergent concerns regarding suicidality and ocular problems require further longitudinal studies to refine the usage guidelines for GLP-1 RAs in susceptible populations.</p>
<section class="tw xbox font-sm" id="t1-dmj-2025-0242"><h3 class="obj_head">Table 1.</h3>
<div class="caption p"><p>Summary of key recent findings on the various side effects of GLP-1 RAs</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" valign="middle" rowspan="1" colspan="1">Adverse effects</th>
<th align="center" valign="middle" rowspan="1" colspan="1">Study design</th>
<th align="center" valign="middle" rowspan="1" colspan="1">Dataset</th>
<th align="center" valign="middle" rowspan="1" colspan="1">Period</th>
<th align="center" valign="middle" rowspan="1" colspan="1">Subjects</th>
<th align="center" valign="middle" rowspan="1" colspan="1">Target</th>
<th align="center" valign="middle" rowspan="1" colspan="1">Comparators</th>
<th align="center" valign="middle" rowspan="1" colspan="1">Median follow-up duration</th>
<th align="center" valign="middle" rowspan="1" colspan="1">Results</th>
<th align="center" valign="middle" rowspan="1" colspan="1">Ref</th>
</tr></thead>
<tbody>
<tr>
<td valign="top" align="left" rowspan="5" colspan="1">Intestinal obstruction</td>
<td valign="top" align="left" rowspan="5" colspan="1">Population-based cohort study</td>
<td valign="top" align="left" rowspan="2" colspan="1">UK Clinical Practice Research Datalink</td>
<td valign="top" align="left" rowspan="2" colspan="1">2013–2019</td>
<td valign="top" align="left" rowspan="2" colspan="1">T2DM</td>
<td valign="top" align="left" rowspan="1" colspan="1">GLP-1 RAs</td>
<td valign="top" align="left" rowspan="2" colspan="1">SGLT-2 inhibitors</td>
<td valign="top" align="left" rowspan="1" colspan="1">0.9 years for GLP-1 RAs</td>
<td valign="top" align="left" rowspan="1" colspan="1">GLP-1 RAs associated with increased intestinal obstruction risk (HR, 1.69; 95% CI, 1.04–2.74).</td>
<td valign="top" align="center" rowspan="2" colspan="1">[<a href="#b11-dmj-2025-0242" class="usa-link" aria-describedby="b11-dmj-2025-0242">11</a>]</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">DPP-4 inhibitors</td>
<td valign="top" align="left" rowspan="1" colspan="1">0.5 years for SGLT-2 inhibitors</td>
<td valign="top" align="left" rowspan="1" colspan="1">DPP-4 inhibitors also increased the risk (HR, 2.59; 95% CI, 1.52–4.42).</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="2" colspan="1">Administrative and health registers in Sweden, Denmark, and Norway</td>
<td valign="top" align="left" rowspan="2" colspan="1">2013–2021</td>
<td valign="top" align="left" rowspan="2" colspan="1">T2DM</td>
<td valign="top" align="left" rowspan="1" colspan="1">GLP-1 RAs</td>
<td valign="top" align="left" rowspan="2" colspan="1">SGLT-2 inhibitors</td>
<td valign="top" align="left" rowspan="1" colspan="1">0.9 years for GLP-1 RAs</td>
<td valign="top" align="left" rowspan="2" colspan="1">Neither DPP4 inhibitors (HR, 1.13; 95% CI, 0.96–1.34) nor GLP-1 RAs (HR, 0.83; 95% CI, 0.69–1.01) increased intestinal obstruction risk.</td>
<td valign="top" align="center" rowspan="2" colspan="1">[<a href="#b12-dmj-2025-0242" class="usa-link" aria-describedby="b12-dmj-2025-0242">12</a>]</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">DPP-4 inhibitors</td>
<td valign="top" align="left" rowspan="1" colspan="1">0.8 years for SGLT-2 inhibitors</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">Danish health registries</td>
<td valign="top" align="left" rowspan="1" colspan="1">Before 2018–2024</td>
<td valign="top" align="left" rowspan="1" colspan="1">Irritable bowel disease</td>
<td valign="top" align="left" rowspan="1" colspan="1">GLP-1 Ras exposure</td>
<td valign="top" align="left" rowspan="1" colspan="1">GLP-1 RAs non-exposure</td>
<td valign="top" align="left" rowspan="1" colspan="1">348,687 Person-years</td>
<td valign="top" align="left" rowspan="1" colspan="1">Adjusted hazard ratios indicated no increased risk associated with GLP-1 RA exposure (aHR, 0.57; 95% CI, 0.36–0.88).</td>
<td valign="top" align="center" rowspan="1" colspan="1">[<a href="#b13-dmj-2025-0242" class="usa-link" aria-describedby="b13-dmj-2025-0242">13</a>]</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="3" colspan="1">Aspiration pneumonia</td>
<td valign="top" align="left" rowspan="3" colspan="1">Population-based cohort study</td>
<td valign="top" align="left" rowspan="1" colspan="1">TriNetX dataset</td>
<td valign="top" align="left" rowspan="1" colspan="1">2018–2020</td>
<td valign="top" align="left" rowspan="1" colspan="1">Mostly T2DM</td>
<td valign="top" align="left" rowspan="1" colspan="1">GLP-1 Ras exposure</td>
<td valign="top" align="left" rowspan="1" colspan="1">GLP-1 RAs non-exposure</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">GLP-1 RA use showed a higher incidence rate of aspiration pneumonia (HR, 1.33; 95% CI, 1.02–1.74).</td>
<td valign="top" align="center" rowspan="1" colspan="1">[<a href="#b20-dmj-2025-0242" class="usa-link" aria-describedby="b20-dmj-2025-0242">20</a>]</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">Truven Health Analytics MarketScan databases</td>
<td valign="top" align="left" rowspan="1" colspan="1">2005–2021</td>
<td valign="top" align="left" rowspan="1" colspan="1">T2DM</td>
<td valign="top" align="left" rowspan="1" colspan="1">GLP-1 RAs</td>
<td valign="top" align="left" rowspan="1" colspan="1">DPP-4 inhibitors</td>
<td valign="top" align="left" rowspan="1" colspan="1">Within 14 days after endoscopy</td>
<td valign="top" align="left" rowspan="1" colspan="1">GLP1-RA use was not associated with an increased risk of pulmonary complications after upper endoscopy (aRR, 0.93; 95% CI, 0.60–1.43).</td>
<td valign="top" align="center" rowspan="1" colspan="1">[<a href="#b21-dmj-2025-0242" class="usa-link" aria-describedby="b21-dmj-2025-0242">21</a>]</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">US commercial healthcare databases</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">T2DM</td>
<td valign="top" align="left" rowspan="1" colspan="1">GLP-1 RAs</td>
<td valign="top" align="left" rowspan="1" colspan="1">SGLT-2 inhibitors</td>
<td valign="top" align="left" rowspan="1" colspan="1">Within 1–3 days after endoscopy</td>
<td valign="top" align="left" rowspan="1" colspan="1">GLP-1 RA use was not associated with an increased risk of pulmonary aspiration compared (PRR, 0.98; 95% CI, 0.73–1.31).</td>
<td valign="top" align="center" rowspan="1" colspan="1">[<a href="#b22-dmj-2025-0242" class="usa-link" aria-describedby="b22-dmj-2025-0242">22</a>]</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="6" colspan="1">Hepato-biliary diseases</td>
<td valign="top" align="left" rowspan="1" colspan="1">
<em>Post hoc</em> analysis of RCTs</td>
<td valign="top" align="left" rowspan="1" colspan="1">The LEADER trial involved 410 sites across 32 countries</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">T2DM with high risk for CVD</td>
<td valign="top" align="left" rowspan="1" colspan="1">Liraglutide 1.8 mg</td>
<td valign="top" align="left" rowspan="1" colspan="1">Placebo</td>
<td valign="top" align="left" rowspan="1" colspan="1">3.8 years</td>
<td valign="top" align="left" rowspan="1" colspan="1">Liraglutide increased the risk of gallbladder or biliary tract-related events (HR, 1.60; 95% CI, 1.23–2.09).</td>
<td valign="top" align="center" rowspan="1" colspan="1">[<a href="#b34-dmj-2025-0242" class="usa-link" aria-describedby="b34-dmj-2025-0242">34</a>]</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">Meta-analysis of RCTs</td>
<td valign="top" align="left" rowspan="1" colspan="1">76 Randomized trials of GLP-1 RA medications</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">Mostly T2DM</td>
<td valign="top" align="left" rowspan="1" colspan="1">GLP-1 RAs</td>
<td valign="top" align="left" rowspan="1" colspan="1">Active and placebo</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">GLP-1 RAs treatment significantly increased the risk of gallbladder or biliary diseases (RR, 1.37; 95% CI, 1.23–1.52).</td>
<td valign="top" align="center" rowspan="1" colspan="1">[<a href="#b39-dmj-2025-0242" class="usa-link" aria-describedby="b39-dmj-2025-0242">39</a>]</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="4" colspan="1">Population-based cohort study</td>
<td valign="top" align="left" rowspan="2" colspan="1">UK Clinical Practice Research Datalink</td>
<td valign="top" align="left" rowspan="2" colspan="1">2007–2013</td>
<td valign="top" align="left" rowspan="2" colspan="1">T2DM</td>
<td valign="top" align="left" rowspan="1" colspan="1">GLP-1 RAs</td>
<td valign="top" align="left" rowspan="2" colspan="1">Two OHAs</td>
<td valign="top" align="left" rowspan="2" colspan="1">3.2 years</td>
<td valign="top" align="left" rowspan="2" colspan="1">GLP-1 RAs increased the risk of bile duct/gallbladder disease (HR, 1.79; 95% CI, 1.21–2.67) and undergoing cholecystectomy (HR, 2.08; 95% CI, 1.08–4.02).</td>
<td valign="top" align="center" rowspan="2" colspan="1">[<a href="#b35-dmj-2025-0242" class="usa-link" aria-describedby="b35-dmj-2025-0242">35</a>]</td>
</tr>
<tr><td valign="top" align="left" rowspan="1" colspan="1">DPP-4 inhibitors</td></tr>
<tr>
<td valign="top" align="left" rowspan="2" colspan="1">Taiwan National Health Insurance Database</td>
<td valign="top" align="left" rowspan="2" colspan="1">2012–2018</td>
<td valign="top" align="left" rowspan="2" colspan="1">T2DM</td>
<td valign="top" align="left" rowspan="2" colspan="1">GLP-1 RAs</td>
<td valign="top" align="left" rowspan="2" colspan="1">SGLT-2 inhibitors</td>
<td valign="top" align="left" rowspan="1" colspan="1">1.4 years for GLP-1 RAs</td>
<td valign="top" align="left" rowspan="2" colspan="1">GLP-1 RAs increased the risk of acute cholecystitis or cholecystectomy (HR, 1.22; 95% CI, 0.92–1.62).</td>
<td valign="top" align="center" rowspan="2" colspan="1">[<a href="#b36-dmj-2025-0242" class="usa-link" aria-describedby="b36-dmj-2025-0242">36</a>]</td>
</tr>
<tr><td valign="top" align="left" rowspan="1" colspan="1">1.8 years for SGLT-2 inhibitors</td></tr>
<tr>
<td valign="top" align="left" rowspan="10" colspan="1">Pancreas diseases</td>
<td valign="top" align="left" rowspan="2" colspan="1">Meta-analysis of RCTs</td>
<td valign="top" align="left" rowspan="2" colspan="1">Data from 11 CVOTs with GLP-1 RAs and DPP-4 inhibitors</td>
<td valign="top" align="left" rowspan="2" colspan="1"></td>
<td valign="top" align="left" rowspan="2" colspan="1">T2DM</td>
<td valign="top" align="left" rowspan="1" colspan="1">GLP-1 RAs</td>
<td valign="top" align="left" rowspan="2" colspan="1">Active and placebo</td>
<td valign="top" align="left" rowspan="2" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">Neither GLP-1 RAs (RR, 1.14; 95% CI, 0.77–1.70) nor DPP-4 inhibitors (RR, 0.94; 95% CI, 0.52–1.68) significantly elevated the risk of pancreatic cancer.</td>
<td valign="top" align="center" rowspan="2" colspan="1">[<a href="#b53-dmj-2025-0242" class="usa-link" aria-describedby="b53-dmj-2025-0242">53</a>]</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">DPP-4 inhibitors</td>
<td valign="top" align="left" rowspan="1" colspan="1">DPP-4 inhibitors increased the risk of acute pancreatitis (RR, 1.75; 95% CI, 1.14–2.70).</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">Meta-analysis of RCTs</td>
<td valign="top" align="left" rowspan="1" colspan="1">28 RCTs for assessing safety of GLP-1 RAs</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">T2DM</td>
<td valign="top" align="left" rowspan="1" colspan="1">GLP-1 RAs</td>
<td valign="top" align="left" rowspan="1" colspan="1">Active and placebo</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">The incidence of pancreatitis (MH-OR, 0.93; 95% CI, 0.65–1.34) and pancreatic cancer (MH-OR, 0.94; 95% CI, 0.52–1.70) with GLP-1 RA was not significantly different.</td>
<td valign="top" align="center" rowspan="1" colspan="1">[<a href="#b58-dmj-2025-0242" class="usa-link" aria-describedby="b58-dmj-2025-0242">58</a>]</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="7" colspan="1">Population-based cohort study</td>
<td valign="top" align="left" rowspan="2" colspan="1">Six CNODES database sites from Canada, the US, and the UK</td>
<td valign="top" align="left" rowspan="2" colspan="1">2007–2014</td>
<td valign="top" align="left" rowspan="2" colspan="1">T2DM</td>
<td valign="top" align="left" rowspan="1" colspan="1">GLP-1 RAs</td>
<td valign="top" align="left" rowspan="2" colspan="1">Sulfonyl-urea</td>
<td valign="top" align="left" rowspan="2" colspan="1">1.3–2.8 years</td>
<td valign="top" align="left" rowspan="2" colspan="1">Compared with sulfonylureas, incretin-based drugs were not associated with an increased risk of pancreatic cancer (HR, 1.02; 95% CI, 0.84– 1.23).</td>
<td valign="top" align="center" rowspan="2" colspan="1">[<a href="#b55-dmj-2025-0242" class="usa-link" aria-describedby="b55-dmj-2025-0242">55</a>]</td>
</tr>
<tr><td valign="top" align="left" rowspan="1" colspan="1">DPP-4 inhibitors</td></tr>
<tr>
<td valign="top" align="left" rowspan="2" colspan="1">Veterans Health Administration</td>
<td valign="top" align="left" rowspan="2" colspan="1">2011–2021</td>
<td valign="top" align="left" rowspan="2" colspan="1">T2DM</td>
<td valign="top" align="left" rowspan="1" colspan="1">GLP-1 RAs</td>
<td valign="top" align="left" rowspan="2" colspan="1">TZD</td>
<td valign="top" align="left" rowspan="2" colspan="1"></td>
<td valign="top" align="left" rowspan="2" colspan="1">An adjusted odds ratio found no statistical difference in pancreatitis cases between the TZD and incretin cohorts (aOR, 0.94; 95% CI, 0.75–1.18).</td>
<td valign="top" align="center" rowspan="2" colspan="1">[<a href="#b56-dmj-2025-0242" class="usa-link" aria-describedby="b56-dmj-2025-0242">56</a>]</td>
</tr>
<tr><td valign="top" align="left" rowspan="1" colspan="1">DPP-4 inhibitors</td></tr>
<tr>
<td valign="top" align="left" rowspan="2" colspan="1">US administrative database</td>
<td valign="top" align="left" rowspan="2" colspan="1">2005–2008</td>
<td valign="top" align="left" rowspan="2" colspan="1">T2DM</td>
<td valign="top" align="left" rowspan="1" colspan="1">GLP-1 RAs</td>
<td valign="top" align="left" rowspan="2" colspan="1">Non-GLP-1 based therapy</td>
<td valign="top" align="left" rowspan="2" colspan="1"></td>
<td valign="top" align="left" rowspan="2" colspan="1">GLP-1 based therapy was associated with an increased risk of acute pancreatitis compared with nonusers (aOR, 2.07; 95% CI, 1.36-3.13).</td>
<td valign="top" align="center" rowspan="2" colspan="1">[<a href="#b59-dmj-2025-0242" class="usa-link" aria-describedby="b59-dmj-2025-0242">59</a>]</td>
</tr>
<tr><td valign="top" align="left" rowspan="1" colspan="1">DPP-4 inhibitors</td></tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">TriNetX dataset</td>
<td valign="top" align="left" rowspan="1" colspan="1">2013–2019</td>
<td valign="top" align="left" rowspan="1" colspan="1">T2DM</td>
<td valign="top" align="left" rowspan="1" colspan="1">GLP-1 RAs</td>
<td valign="top" align="left" rowspan="1" colspan="1">Non-GLP-1 RA</td>
<td valign="top" align="left" rowspan="1" colspan="1">5 years</td>
<td valign="top" align="left" rowspan="1" colspan="1">GLP-1RAs were associated with a lower risk of pancreatic cancer compared to insulin (HR, 0.42; 95% CI, 0.33–0.53), metformin (HR,0.74; 95% CI, 0.58–0.95), DPP-4 inhibitors (HR, 0.77; 95% CI, 0.66–0.90), SGLT-2 inhibitors (HR, 0.71; 95% CI, 0.59–0.85), sulfonylurea (HR, 0.74; 95% CI 0.63–0.88), and TZD (HR, 0.82, 95% CI, 0.69–0.99).</td>
<td valign="top" align="center" rowspan="1" colspan="1">[<a href="#b61-dmj-2025-0242" class="usa-link" aria-describedby="b61-dmj-2025-0242">61</a>]</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="10" colspan="1">Psychiatric diseases</td>
<td valign="top" align="left" rowspan="2" colspan="1">
<em>Post hoc</em> analysis of RCTs</td>
<td valign="top" align="left" rowspan="2" colspan="1">STEP 1, 2, 3, and STEP 5 trials</td>
<td valign="top" align="left" rowspan="2" colspan="1">2018–2021</td>
<td valign="top" align="left" rowspan="2" colspan="1">OW/OB (T2DM in STEP 2)</td>
<td valign="top" align="left" rowspan="2" colspan="1">Semaglutide 2.4 mg</td>
<td valign="top" align="left" rowspan="2" colspan="1">Placebo</td>
<td valign="top" align="left" rowspan="1" colspan="1">STEP 1, 2, and 3: 68 weeks</td>
<td valign="top" align="left" rowspan="2" colspan="1">Semaglutide, 2.4 mg, did not increase the risk of developing depressive symptoms (OR 0.63; 95% CI, 0.50–0.79) or suicidal ideation/ behavior.</td>
<td valign="top" align="center" rowspan="2" colspan="1">[<a href="#b75-dmj-2025-0242" class="usa-link" aria-describedby="b75-dmj-2025-0242">75</a>]</td>
</tr>
<tr><td valign="top" align="left" rowspan="1" colspan="1">STEP 5: 104 weeks</td></tr>
<tr>
<td valign="top" align="left" rowspan="7" colspan="1">Population-based cohort study</td>
<td valign="top" align="left" rowspan="2" colspan="1">Valencia Health System Integrated Database (VID)</td>
<td valign="top" align="left" rowspan="2" colspan="1">2015–2021</td>
<td valign="top" align="left" rowspan="2" colspan="1">T2DM, obese</td>
<td valign="top" align="left" rowspan="2" colspan="1">GLP-1 Ras</td>
<td valign="top" align="left" rowspan="2" colspan="1">SGLT-2 inhibitors</td>
<td valign="top" align="left" rowspan="1" colspan="1">992 days for GLP-1 RA</td>
<td valign="top" align="left" rowspan="2" colspan="1">GLP-1 RAs exhibited no increased risk of the incidence of suicidal ideation and self-injury (HR, 1.04; 95% CI, 0.35–3.14).</td>
<td valign="top" align="center" rowspan="2" colspan="1">[<a href="#b76-dmj-2025-0242" class="usa-link" aria-describedby="b76-dmj-2025-0242">76</a>]</td>
</tr>
<tr><td valign="top" align="left" rowspan="1" colspan="1">970 days for SGLT-2 inhibitors</td></tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">Nationwide register data from Sweden and Denmark</td>
<td valign="top" align="left" rowspan="1" colspan="1">2013–2021</td>
<td valign="top" align="left" rowspan="1" colspan="1">Mostly T2DM</td>
<td valign="top" align="left" rowspan="1" colspan="1">GLP-1 Ras</td>
<td valign="top" align="left" rowspan="1" colspan="1">SGLT-2 inhibitors</td>
<td valign="top" align="left" rowspan="1" colspan="1">2.5 years</td>
<td valign="top" align="left" rowspan="1" colspan="1">GLP-1 RAs did not increase the risk of suicide death (HR, 1.25; 95% CI, 0.83–1.88).</td>
<td valign="top" align="center" rowspan="1" colspan="1">[<a href="#b77-dmj-2025-0242" class="usa-link" aria-describedby="b77-dmj-2025-0242">77</a>]</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="2" colspan="1">UK Clinical Practice Research Datalink</td>
<td valign="top" align="left" rowspan="2" colspan="1">2007–2020</td>
<td valign="top" align="left" rowspan="2" colspan="1">T2DM</td>
<td valign="top" align="left" rowspan="2" colspan="1">GLP-1 RAs</td>
<td valign="top" align="left" rowspan="1" colspan="1">DPP-4 inhibitors</td>
<td valign="top" align="left" rowspan="2" colspan="1">1.3 years</td>
<td valign="top" align="left" rowspan="2" colspan="1">GLP-1 RAs did not increase the risk for suicide death (vs. SGLT-2 inhibitor, HR, 0.91; 95% CI, 0.73–1.12) (vs. DPP-4 inhibitors, HR, 1.02; 95% CI, 0.85–1.23).</td>
<td valign="top" align="center" rowspan="2" colspan="1">[<a href="#b78-dmj-2025-0242" class="usa-link" aria-describedby="b78-dmj-2025-0242">78</a>]</td>
</tr>
<tr><td valign="top" align="left" rowspan="1" colspan="1">SGLT-2 inhibitors</td></tr>
<tr>
<td valign="top" align="left" rowspan="2" colspan="1">TriNetX dataset</td>
<td valign="top" align="left" rowspan="1" colspan="1">T2DM: 2017–2021</td>
<td valign="top" align="left" rowspan="2" colspan="1">T2DM, OW/OB</td>
<td valign="top" align="left" rowspan="2" colspan="1">Semaglutide</td>
<td valign="top" align="left" rowspan="2" colspan="1">Non-GLP-1 RA AOM</td>
<td valign="top" align="left" rowspan="1" colspan="1">172.9 days for semaglutide</td>
<td valign="top" align="left" rowspan="2" colspan="1">Semaglutide was associated with a lower risk for incident (HR, 0.27; 95% CI, 0.20–0.36) and recurrent (HR, 0.44; 95% CI, 0.32–0.60) suicidal ideation.</td>
<td valign="top" align="center" rowspan="2" colspan="1">[<a href="#b80-dmj-2025-0242" class="usa-link" aria-describedby="b80-dmj-2025-0242">80</a>]</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">OW/OB: 2021–2022</td>
<td valign="top" align="left" rowspan="1" colspan="1">167.2 days for non-GLP-1 RA AOM</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">Meta-analysis of observational cohort and case-control studies</td>
<td valign="top" align="left" rowspan="1" colspan="1">Various 11 studies on GLP-1 RAs and their association with suicidal ideation</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">T2DM, OW/OB, general users of GLP-1 RAs</td>
<td valign="top" align="left" rowspan="1" colspan="1">GLP-1 RAs</td>
<td valign="top" align="left" rowspan="1" colspan="1">Active and placebo</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">No statistically significant differences were observed in suicidal outcomes between GLP-1 RAs and other antihyperglycemic drugs (RR, 0.57; 95% CI, 0.08–4.21).</td>
<td valign="top" align="center" rowspan="1" colspan="1">[<a href="#b79-dmj-2025-0242" class="usa-link" aria-describedby="b79-dmj-2025-0242">79</a>]</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="8" colspan="1">Ocular diseases</td>
<td valign="top" align="left" rowspan="3" colspan="1">
<em>Post hoc</em> analysis of RCTs</td>
<td valign="top" align="left" rowspan="1" colspan="1">SUSTAIN 6</td>
<td valign="top" align="left" rowspan="1" colspan="1">2013</td>
<td valign="top" align="left" rowspan="1" colspan="1">T2DM</td>
<td valign="top" align="left" rowspan="1" colspan="1">Semaglutide 0.5/1.0 mg</td>
<td valign="top" align="left" rowspan="1" colspan="1">Placebo</td>
<td valign="top" align="left" rowspan="1" colspan="1">2.1 years</td>
<td valign="top" align="left" rowspan="1" colspan="1">Semaglutide increase the risk of diabetic retinopathy complications (HR, 1.76; 95% CI, 1.11–2.78).</td>
<td valign="top" align="center" rowspan="1" colspan="1">[<a href="#b89-dmj-2025-0242" class="usa-link" aria-describedby="b89-dmj-2025-0242">89</a>]</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">LEADER</td>
<td valign="top" align="left" rowspan="1" colspan="1">2010–2015</td>
<td valign="top" align="left" rowspan="1" colspan="1">T2DM with high risk for CVD</td>
<td valign="top" align="left" rowspan="1" colspan="1">Liraglutide</td>
<td valign="top" align="left" rowspan="1" colspan="1">Placebo</td>
<td valign="top" align="left" rowspan="1" colspan="1">3.8 years</td>
<td valign="top" align="left" rowspan="1" colspan="1">Liraglutide exhibited no increased risk of the incidence of retinopathy events (HR, 1.15; 95% CI, 0.87–1.52).</td>
<td valign="top" align="center" rowspan="1" colspan="1">[<a href="#b33-dmj-2025-0242" class="usa-link" aria-describedby="b33-dmj-2025-0242">33</a>]</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">REWIND</td>
<td valign="top" align="left" rowspan="1" colspan="1">2011–2018</td>
<td valign="top" align="left" rowspan="1" colspan="1">T2DM ±CVD</td>
<td valign="top" align="left" rowspan="1" colspan="1">Dulaglutide 1.5 mg weekly</td>
<td valign="top" align="left" rowspan="1" colspan="1">Placebo</td>
<td valign="top" align="left" rowspan="1" colspan="1">5.4 years</td>
<td valign="top" align="left" rowspan="1" colspan="1">Dulaglutide resulted in inferior ocular outcomes (HR, 1.24; 95% CI, 0.92–1.68).</td>
<td valign="top" align="center" rowspan="1" colspan="1">[<a href="#b38-dmj-2025-0242" class="usa-link" aria-describedby="b38-dmj-2025-0242">38</a>]</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">Meta-analysis of RCTs</td>
<td valign="top" align="left" rowspan="1" colspan="1">13 Studies on GLP-1 RAs</td>
<td valign="top" align="left" rowspan="1" colspan="1">2008–2021</td>
<td valign="top" align="left" rowspan="1" colspan="1">T2DM</td>
<td valign="top" align="left" rowspan="1" colspan="1">GLP-1 RAs</td>
<td valign="top" align="left" rowspan="1" colspan="1">Placebo/standard care</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">GLP-1 RAs increase the risk of diabetic retinopathy (HR, 1.23; 95% CI, 1.05–1.44).</td>
<td valign="top" align="center" rowspan="1" colspan="1">[<a href="#b90-dmj-2025-0242" class="usa-link" aria-describedby="b90-dmj-2025-0242">90</a>]</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="4" colspan="1">Population-based cohort study</td>
<td valign="top" align="left" rowspan="1" colspan="1">TriNetX dataset</td>
<td valign="top" align="left" rowspan="1" colspan="1">2010–2023</td>
<td valign="top" align="left" rowspan="1" colspan="1">T2DM</td>
<td valign="top" align="left" rowspan="1" colspan="1">GLP-1 RAs+insulin</td>
<td valign="top" align="left" rowspan="1" colspan="1">SGLT-2 inhibitor+insulin</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">GLP-1 RA therapy combined with insulin was associated with a higher risk of diabetic retinopathy (HR, 1.21; 95% CI, 1.15–1.26) and diabetic macular edema (HR, 1.13; 95% CI, 1.06–1.21) compared to SGLT-2 inhibitor therapy with insulin.</td>
<td valign="top" align="center" rowspan="1" colspan="1">[<a href="#b93-dmj-2025-0242" class="usa-link" aria-describedby="b93-dmj-2025-0242">93</a>]</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">Cleveland Clinic Cole Eye Institute</td>
<td valign="top" align="left" rowspan="1" colspan="1">2012–2023</td>
<td valign="top" align="left" rowspan="1" colspan="1">T2DM</td>
<td valign="top" align="left" rowspan="1" colspan="1">GLP-1 RAs</td>
<td valign="top" align="left" rowspan="1" colspan="1">SGLT2 inhibitors</td>
<td valign="top" align="left" rowspan="1" colspan="1">1.54 years for GLP-1 RAs; 1.38 years for SGLT-2 inhibitor</td>
<td valign="top" align="left" rowspan="1" colspan="1">No difference in diabetic retinopathy progression between GLP-1 RAs and SGLT-2 inhibitors after propensity matching (OR, 0.33; 95% CI, 0.11–1.03)</td>
<td valign="top" align="center" rowspan="1" colspan="1">[<a href="#b94-dmj-2025-0242" class="usa-link" aria-describedby="b94-dmj-2025-0242">94</a>]</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">Neuro-ophthalmology registry</td>
<td valign="top" align="left" rowspan="1" colspan="1">2017–2023</td>
<td valign="top" align="left" rowspan="1" colspan="1">T2DM, OW/OB</td>
<td valign="top" align="left" rowspan="1" colspan="1">Semaglutide</td>
<td valign="top" align="left" rowspan="1" colspan="1">Non-semaglutide</td>
<td valign="top" align="left" rowspan="1" colspan="1">33.3 months for semaglutide, 34.5 months for nonsemaglutide</td>
<td valign="top" align="left" rowspan="1" colspan="1">Semaglutide increased the risk for NAION in T2DM (HR, 4.28; 95% CI, 1.62–11.29) and in obesity (HR, 7.64; 95% CI, 2.21–26.36) compared to non-semaglutide.</td>
<td valign="top" align="center" rowspan="1" colspan="1">[<a href="#b97-dmj-2025-0242" class="usa-link" aria-describedby="b97-dmj-2025-0242">97</a>]</td>
</tr>
<tr>
<td valign="top" align="left" rowspan="1" colspan="1">TriNetX dataset</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">T2DM, OW/OB</td>
<td valign="top" align="left" rowspan="1" colspan="1">Semaglutide/GLP-1 RA</td>
<td valign="top" align="left" rowspan="1" colspan="1">Non-GLP-1 RA</td>
<td valign="top" align="left" rowspan="1" colspan="1"></td>
<td valign="top" align="left" rowspan="1" colspan="1">Semaglutide and GLP-1 RAs had no increased risk of NAION in patients with T2DM or high BMI compared to non-GLP-1 RAs.</td>
<td valign="top" align="center" rowspan="1" colspan="1">[<a href="#b99-dmj-2025-0242" class="usa-link" aria-describedby="b99-dmj-2025-0242">99</a>]</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/t1-dmj-2025-0242/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="fn4"><p>GLP-1 RA, glucagon-like peptide-1 receptor agonist; T2DM, type 2 diabetes mellitus; DPP-4, dipeptidylpeptidase-4; SGLT-2, sodium-glucose cotransporter-2; HR, hazard ratio; CI, confidence interval; aHR, adjusted hazard ratio; aRR, adjusted relative risk; PRR, proportional reporting ratio; RCT, randomized controlled trial; LEADER, Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results; CVD, cardiovascular disease; RR, relative risk; OHA, oral hypoglycemic agent; CVOT, cardiovascular outcome trial; MH-OR, Mantel-Haenszel odds ratio; CNODES, Canadian Network for Observational Drug Effect Studies; TZD, thiazolidinedione; aOR, adjusted odds ratio; STEP, Semaglutide Treatment Effect in People with Obesity; OW, overweight; OB, obese; AOM, anti-obesity medication; SUSTAIN, Semaglutide Unabated Sustainability in Treatment of T2DM; REWIND, Researching cardiovascular Events with a Weekly Incretin in Diabetes; NAION, non-arteritic anterior ischemic optic neuropathy; BMI, body mass index.</p></div></div></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="fn1">
<p>
<strong>CONFLICTS OF INTEREST</strong>
</p>
<p>No potential conflict of interest relevant to this article was reported.</p>
</div>
<div class="fn p" id="fn2">
<p>
<strong>FUNDING</strong>
</p>
<p>This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), South Korea, funded by the Ministry of Education (NRF-2021R1A2C2008792).</p>
</div>
<div class="fn p" id="fn3">
<p>
<strong>ACKNOWLEDGMENTS</strong>
</p>
<p>None</p>
</div>
</div></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">REFERENCES</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="b1-dmj-2025-0242">
<span class="label">1.</span><cite>Marathe CS, Rayner CK, Jones KL, Horowitz M. Effects of GLP-1 and incretin-based therapies on gastrointestinal motor function. Exp Diabetes Res. 2011;2011:279530. doi: 10.1155/2011/279530.</cite> [<a href="https://doi.org/10.1155/2011/279530" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3124003/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21747825/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Exp%20Diabetes%20Res&amp;title=Effects%20of%20GLP-1%20and%20incretin-based%20therapies%20on%20gastrointestinal%20motor%20function&amp;author=CS%20Marathe&amp;author=CK%20Rayner&amp;author=KL%20Jones&amp;author=M%20Horowitz&amp;volume=2011&amp;publication_year=2011&amp;pages=279530&amp;pmid=21747825&amp;doi=10.1155/2011/279530&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b2-dmj-2025-0242">
<span class="label">2.</span><cite>Nauck MA, Quast DR, Wefers J, Meier JJ. GLP-1 receptor agonists the treatment of type 2 diabetes: state-of-the-art. Mol Metab. 2021;46:101102. doi: 10.1016/j.molmet.2020.101102.</cite> [<a href="https://doi.org/10.1016/j.molmet.2020.101102" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8085572/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33068776/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Mol%20Metab&amp;title=GLP-1%20receptor%20agonists%20the%20treatment%20of%20type%202%20diabetes:%20state-of-the-art&amp;author=MA%20Nauck&amp;author=DR%20Quast&amp;author=J%20Wefers&amp;author=JJ%20Meier&amp;volume=46&amp;publication_year=2021&amp;pages=101102&amp;pmid=33068776&amp;doi=10.1016/j.molmet.2020.101102&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b3-dmj-2025-0242">
<span class="label">3.</span><cite>Ferhatbegovic L, Mrsic D, Macic-Dzankovic A. The benefits of GLP1 receptors in cardiovascular diseases. Front Clin Diabetes Healthc. 2023;4:1293926. doi: 10.3389/fcdhc.2023.1293926.</cite> [<a href="https://doi.org/10.3389/fcdhc.2023.1293926" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10739421/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38143794/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Clin%20Diabetes%20Healthc&amp;title=The%20benefits%20of%20GLP1%20receptors%20in%20cardiovascular%20diseases&amp;author=L%20Ferhatbegovic&amp;author=D%20Mrsic&amp;author=A%20Macic-Dzankovic&amp;volume=4&amp;publication_year=2023&amp;pages=1293926&amp;pmid=38143794&amp;doi=10.3389/fcdhc.2023.1293926&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b4-dmj-2025-0242">
<span class="label">4.</span><cite>Giugliano D, Scappaticcio L, Longo M, Caruso P, Maiorino MI, Bellastella G, et al.  GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021;20:189. doi: 10.1186/s12933-021-01366-8.</cite> [<a href="https://doi.org/10.1186/s12933-021-01366-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8442438/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34526024/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Cardiovasc%20Diabetol&amp;title=GLP-1%20receptor%20agonists%20and%20cardiorenal%20outcomes%20in%20type%202%20diabetes:%20an%20updated%20meta-analysis%20of%20eight%20CVOTs&amp;author=D%20Giugliano&amp;author=L%20Scappaticcio&amp;author=M%20Longo&amp;author=P%20Caruso&amp;author=MI%20Maiorino&amp;volume=20&amp;publication_year=2021&amp;pages=189&amp;pmid=34526024&amp;doi=10.1186/s12933-021-01366-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b5-dmj-2025-0242">
<span class="label">5.</span><cite>Moll H, Frey E, Gerber P, Geidl B, Kaufmann M, Braun J, et al.  GLP-1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit-harm modelling study. EClinicalMedicine. 2024;73:102661. doi: 10.1016/j.eclinm.2024.102661.</cite> [<a href="https://doi.org/10.1016/j.eclinm.2024.102661" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11154119/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38846069/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=EClinicalMedicine&amp;title=GLP-1%20receptor%20agonists%20for%20weight%20reduction%20in%20people%20living%20with%20obesity%20but%20without%20diabetes:%20a%20living%20benefit-harm%20modelling%20study&amp;author=H%20Moll&amp;author=E%20Frey&amp;author=P%20Gerber&amp;author=B%20Geidl&amp;author=M%20Kaufmann&amp;volume=73&amp;publication_year=2024&amp;pages=102661&amp;pmid=38846069&amp;doi=10.1016/j.eclinm.2024.102661&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b6-dmj-2025-0242">
<span class="label">6.</span><cite>Osei SP, Akomaning E, Florut TF, Sodhi M, Lacy BE, Aldhaleei WA, et al.  Gastrointestinal safety assessment of GLP-1 receptor agonists in the US: a real-world adverse events analysis from the FAERS database. Diagnostics (Basel) 2024;14:2829. doi: 10.3390/diagnostics14242829.</cite> [<a href="https://doi.org/10.3390/diagnostics14242829" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11675942/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39767190/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diagnostics%20(Basel)&amp;title=Gastrointestinal%20safety%20assessment%20of%20GLP-1%20receptor%20agonists%20in%20the%20US:%20a%20real-world%20adverse%20events%20analysis%20from%20the%20FAERS%20database&amp;author=SP%20Osei&amp;author=E%20Akomaning&amp;author=TF%20Florut&amp;author=M%20Sodhi&amp;author=BE%20Lacy&amp;volume=14&amp;publication_year=2024&amp;pages=2829&amp;pmid=39767190&amp;doi=10.3390/diagnostics14242829&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b7-dmj-2025-0242">
<span class="label">7.</span><cite>Ghusn W, De la Rosa A, Sacoto D, Cifuentes L, Campos A, Feris F, et al.  Weight loss outcomes associated with semaglutide treatment for patients with overweight or obesity. JAMA Netw Open. 2022;5:e2231982.  doi: 10.1001/jamanetworkopen.2022.31982.</cite> [<a href="https://doi.org/10.1001/jamanetworkopen.2022.31982" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9486455/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36121652/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Netw%20Open&amp;title=Weight%20loss%20outcomes%20associated%20with%20semaglutide%20treatment%20for%20patients%20with%20overweight%20or%20obesity&amp;author=W%20Ghusn&amp;author=A%20De%20la%20Rosa&amp;author=D%20Sacoto&amp;author=L%20Cifuentes&amp;author=A%20Campos&amp;volume=5&amp;publication_year=2022&amp;pages=e2231982&amp;pmid=36121652&amp;doi=10.1001/jamanetworkopen.2022.31982&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b8-dmj-2025-0242">
<span class="label">8.</span><cite>Drucker DJ. Efficacy and safety of GLP-1 medicines for type 2 diabetes and obesity. Diabetes Care. 2024;47:1873–88. doi: 10.2337/dci24-0003.</cite> [<a href="https://doi.org/10.2337/dci24-0003" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38843460/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&amp;title=Efficacy%20and%20safety%20of%20GLP-1%20medicines%20for%20type%202%20diabetes%20and%20obesity&amp;author=DJ%20Drucker&amp;volume=47&amp;publication_year=2024&amp;pages=1873-88&amp;pmid=38843460&amp;doi=10.2337/dci24-0003&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b9-dmj-2025-0242">
<span class="label">9.</span><cite> European Medicines Agency. Pharmacovigilance Risk Assessment Committee (PRAC): minutes of the meeting 7-10 January 2013. Available from:  <a href="https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-7-10-january-2013_en.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.ema.europa.eu/en/documents/minutes/minutes-prac-meeting-7-10-january-2013_en.pdf</a> (cited 2025 Jun 11)</cite>
</li>
<li id="b10-dmj-2025-0242">
<span class="label">10.</span><cite>Gudin B, Ladhari C, Robin P, Laroche ML, Babai S, Hillaire-Buys D, et al.  Incretin-based drugs and intestinal obstruction: a pharmacovigilance study. Therapie. 2020;75:641–7. doi: 10.1016/j.therap.2020.02.024.</cite> [<a href="https://doi.org/10.1016/j.therap.2020.02.024" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32418731/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Therapie&amp;title=Incretin-based%20drugs%20and%20intestinal%20obstruction:%20a%20pharmacovigilance%20study&amp;author=B%20Gudin&amp;author=C%20Ladhari&amp;author=P%20Robin&amp;author=ML%20Laroche&amp;author=S%20Babai&amp;volume=75&amp;publication_year=2020&amp;pages=641-7&amp;pmid=32418731&amp;doi=10.1016/j.therap.2020.02.024&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b11-dmj-2025-0242">
<span class="label">11.</span><cite>Faillie JL, Yin H, Yu OH, Herrero A, Altwegg R, Renoux C, et al.  Incretin-based drugs and risk of intestinal obstruction among patients with type 2 diabetes. Clin Pharmacol Ther. 2022;111:272–82. doi: 10.1002/cpt.2430.</cite> [<a href="https://doi.org/10.1002/cpt.2430" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34587280/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Pharmacol%20Ther&amp;title=Incretin-based%20drugs%20and%20risk%20of%20intestinal%20obstruction%20among%20patients%20with%20type%202%20diabetes&amp;author=JL%20Faillie&amp;author=H%20Yin&amp;author=OH%20Yu&amp;author=A%20Herrero&amp;author=R%20Altwegg&amp;volume=111&amp;publication_year=2022&amp;pages=272-82&amp;pmid=34587280&amp;doi=10.1002/cpt.2430&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b12-dmj-2025-0242">
<span class="label">12.</span><cite>Ueda P, Wintzell V, Melbye M, Eliasson B, Soderling J, Gudbjornsdottir S, et al.  Use of DPP4 inhibitors and GLP-1 receptor agonists and risk of intestinal obstruction: Scandinavian cohort study. Clin Gastroenterol Hepatol. 2024;22:1226–37. doi: 10.1016/j.cgh.2023.08.034.</cite> [<a href="https://doi.org/10.1016/j.cgh.2023.08.034" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37716613/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Gastroenterol%20Hepatol&amp;title=Use%20of%20DPP4%20inhibitors%20and%20GLP-1%20receptor%20agonists%20and%20risk%20of%20intestinal%20obstruction:%20Scandinavian%20cohort%20study&amp;author=P%20Ueda&amp;author=V%20Wintzell&amp;author=M%20Melbye&amp;author=B%20Eliasson&amp;author=J%20Soderling&amp;volume=22&amp;publication_year=2024&amp;pages=1226-37&amp;pmid=37716613&amp;doi=10.1016/j.cgh.2023.08.034&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b13-dmj-2025-0242">
<span class="label">13.</span><cite>Nielsen J, Friedman S, Norgard BM, Knudsen T, Kjeldsen J, Wod M. Glucagon-like peptide 1 receptor agonists are not associated with an increased risk of ileus or intestinal obstruction in patients with inflammatory bowel disease: a danish nationwide cohort study. Inflamm Bowel Dis. 2024 Nov 27; doi: 10.1093/ibd/izae276. [Epub]. </cite> [<a href="https://doi.org/10.1093/ibd/izae276" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39603814/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Inflamm%20Bowel%20Dis&amp;title=Glucagon-like%20peptide%201%20receptor%20agonists%20are%20not%20associated%20with%20an%20increased%20risk%20of%20ileus%20or%20intestinal%20obstruction%20in%20patients%20with%20inflammatory%20bowel%20disease:%20a%20danish%20nationwide%20cohort%20study&amp;author=J%20Nielsen&amp;author=S%20Friedman&amp;author=BM%20Norgard&amp;author=T%20Knudsen&amp;author=J%20Kjeldsen&amp;publication_year=2024&amp;pmid=39603814&amp;doi=10.1093/ibd/izae276&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b14-dmj-2025-0242">
<span class="label">14.</span><cite>Avraham SA, Hossein J, Somri F, Hawash N, Hochman O. Pulmonary aspiration of gastric contents in two patients taking semaglutide for weight loss. Anaesth Rep. 2024;12:e12278.  doi: 10.1002/anr3.12278.</cite> [<a href="https://doi.org/10.1002/anr3.12278" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10788311/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38225986/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Anaesth%20Rep&amp;title=Pulmonary%20aspiration%20of%20gastric%20contents%20in%20two%20patients%20taking%20semaglutide%20for%20weight%20loss&amp;author=SA%20Avraham&amp;author=J%20Hossein&amp;author=F%20Somri&amp;author=N%20Hawash&amp;author=O%20Hochman&amp;volume=12&amp;publication_year=2024&amp;pages=e12278&amp;pmid=38225986&amp;doi=10.1002/anr3.12278&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b15-dmj-2025-0242">
<span class="label">15.</span><cite>Klein SR, Hobai IA. Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report. Can J Anaesth. 2023;70:1394–6. doi: 10.1007/s12630-023-02440-3.</cite> [<a href="https://doi.org/10.1007/s12630-023-02440-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36977934/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Can%20J%20Anaesth&amp;title=Semaglutide,%20delayed%20gastric%20emptying,%20and%20intraoperative%20pulmonary%20aspiration:%20a%20case%20report&amp;author=SR%20Klein&amp;author=IA%20Hobai&amp;volume=70&amp;publication_year=2023&amp;pages=1394-6&amp;pmid=36977934&amp;doi=10.1007/s12630-023-02440-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b16-dmj-2025-0242">
<span class="label">16.</span><cite>Stark JE, Cole JL, Ghazarian RN, Klass MJ. Impact of glucagon-like peptide-1 receptor agonists (GLP-1RA) on food content during esophagogastroduodenoscopy (EGD) Ann Pharmacother. 2022;56:922–6. doi: 10.1177/10600280211055804.</cite> [<a href="https://doi.org/10.1177/10600280211055804" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34726082/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Pharmacother&amp;title=Impact%20of%20glucagon-like%20peptide-1%20receptor%20agonists%20(GLP-1RA)%20on%20food%20content%20during%20esophagogastroduodenoscopy%20(EGD)&amp;author=JE%20Stark&amp;author=JL%20Cole&amp;author=RN%20Ghazarian&amp;author=MJ%20Klass&amp;volume=56&amp;publication_year=2022&amp;pages=922-6&amp;pmid=34726082&amp;doi=10.1177/10600280211055804&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b17-dmj-2025-0242">
<span class="label">17.</span><cite>Sherwin M, Hamburger J, Katz D, DeMaria S., Jr Influence of semaglutide use on the presence of residual gastric solids on gastric ultrasound: a prospective observational study in volunteers without obesity recently started on semaglutide. Can J Anaesth. 2023;70:1300–6. doi: 10.1007/s12630-023-02549-5.</cite> [<a href="https://doi.org/10.1007/s12630-023-02549-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37466909/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Can%20J%20Anaesth&amp;title=Influence%20of%20semaglutide%20use%20on%20the%20presence%20of%20residual%20gastric%20solids%20on%20gastric%20ultrasound:%20a%20prospective%20observational%20study%20in%20volunteers%20without%20obesity%20recently%20started%20on%20semaglutide&amp;author=M%20Sherwin&amp;author=J%20Hamburger&amp;author=D%20Katz&amp;author=S%20DeMaria&amp;volume=70&amp;publication_year=2023&amp;pages=1300-6&amp;pmid=37466909&amp;doi=10.1007/s12630-023-02549-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b18-dmj-2025-0242">
<span class="label">18.</span><cite>Nersessian RS, da Silva LM, Carvalho MA, Silveira SQ, Abib AC, Bellicieri FN, et al.  Relationship between residual gastric content and peri-operative semaglutide use assessed by gastric ultrasound: a prospective observational study. Anaesthesia. 2024;79:1317–24. doi: 10.1111/anae.16454.</cite> [<a href="https://doi.org/10.1111/anae.16454" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39435967/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Anaesthesia&amp;title=Relationship%20between%20residual%20gastric%20content%20and%20peri-operative%20semaglutide%20use%20assessed%20by%20gastric%20ultrasound:%20a%20prospective%20observational%20study&amp;author=RS%20Nersessian&amp;author=LM%20da%20Silva&amp;author=MA%20Carvalho&amp;author=SQ%20Silveira&amp;author=AC%20Abib&amp;volume=79&amp;publication_year=2024&amp;pages=1317-24&amp;pmid=39435967&amp;doi=10.1111/anae.16454&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b19-dmj-2025-0242">
<span class="label">19.</span><cite>Sen S, Potnuru PP, Hernandez N, Goehl C, Praestholm C, Sridhar S, et al.  Glucagon-like peptide-1 receptor agonist use and residual gastric content before anesthesia. JAMA Surg. 2024;159:660–7. doi: 10.1001/jamasurg.2024.0111.</cite> [<a href="https://doi.org/10.1001/jamasurg.2024.0111" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10918573/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38446466/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Surg&amp;title=Glucagon-like%20peptide-1%20receptor%20agonist%20use%20and%20residual%20gastric%20content%20before%20anesthesia&amp;author=S%20Sen&amp;author=PP%20Potnuru&amp;author=N%20Hernandez&amp;author=C%20Goehl&amp;author=C%20Praestholm&amp;volume=159&amp;publication_year=2024&amp;pages=660-7&amp;pmid=38446466&amp;doi=10.1001/jamasurg.2024.0111&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b20-dmj-2025-0242">
<span class="label">20.</span><cite>Yeo YH, Gaddam S, Ng WH, Huang PC, Motility and Metabolic Pharmacoepidemiology Group. Ma KS, et al.  Increased risk of aspiration pneumonia associated with endoscopic procedures among patients with glucagon-like peptide 1 receptor agonist use. Gastroenterology. 2024;167:402–4. doi: 10.1053/j.gastro.2024.03.015.</cite> [<a href="https://doi.org/10.1053/j.gastro.2024.03.015" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38552724/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterology&amp;title=Increased%20risk%20of%20aspiration%20pneumonia%20associated%20with%20endoscopic%20procedures%20among%20patients%20with%20glucagon-like%20peptide%201%20receptor%20agonist%20use&amp;author=YH%20Yeo&amp;author=S%20Gaddam&amp;author=WH%20Ng&amp;author=PC%20Huang&amp;author=KS%20Ma&amp;volume=167&amp;publication_year=2024&amp;pages=402-4&amp;pmid=38552724&amp;doi=10.1053/j.gastro.2024.03.015&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b21-dmj-2025-0242">
<span class="label">21.</span><cite>Barlowe TS, Anderson C, Sandler RS, Subramaniam D, Muratore A, Buse JB, et al.  Glucagon-like peptide-1 receptor agonists do not increase aspiration during upper endoscopy in patients with diabetes. Clin Gastroenterol Hepatol. 2025;23:739–47. doi: 10.1016/j.cgh.2024.04.038.</cite> [<a href="https://doi.org/10.1016/j.cgh.2024.04.038" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11564414/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38759826/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Gastroenterol%20Hepatol&amp;title=Glucagon-like%20peptide-1%20receptor%20agonists%20do%20not%20increase%20aspiration%20during%20upper%20endoscopy%20in%20patients%20with%20diabetes&amp;author=TS%20Barlowe&amp;author=C%20Anderson&amp;author=RS%20Sandler&amp;author=D%20Subramaniam&amp;author=A%20Muratore&amp;volume=23&amp;publication_year=2025&amp;pages=739-47&amp;pmid=38759826&amp;doi=10.1016/j.cgh.2024.04.038&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b22-dmj-2025-0242">
<span class="label">22.</span><cite>Alkabbani W, Suissa K, Gu KD, Cromer SJ, Paik JM, Bykov K, et al.  Glucagon-like peptide-1 receptor agonists before upper gastrointestinal endoscopy and risk of pulmonary aspiration or discontinuation of procedure: cohort study. BMJ. 2024;387:e080340.  doi: 10.1136/bmj-2024-080340.</cite> [<a href="https://doi.org/10.1136/bmj-2024-080340" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11494456/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39438043/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMJ&amp;title=Glucagon-like%20peptide-1%20receptor%20agonists%20before%20upper%20gastrointestinal%20endoscopy%20and%20risk%20of%20pulmonary%20aspiration%20or%20discontinuation%20of%20procedure:%20cohort%20study&amp;author=W%20Alkabbani&amp;author=K%20Suissa&amp;author=KD%20Gu&amp;author=SJ%20Cromer&amp;author=JM%20Paik&amp;volume=387&amp;publication_year=2024&amp;pages=e080340&amp;pmid=39438043&amp;doi=10.1136/bmj-2024-080340&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b23-dmj-2025-0242">
<span class="label">23.</span><cite>Jalleh RJ, Marathe CS, Rayner CK, Jones KL, Umapathysivam MM, Wu T, et al.  Physiology and pharmacology of effects of GLP-1-based therapies on gastric, biliary and intestinal motility. Endocrinology. 2024;166:bqae155. doi: 10.1210/endocr/bqae155.</cite> [<a href="https://doi.org/10.1210/endocr/bqae155" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11630531/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39568409/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Endocrinology&amp;title=Physiology%20and%20pharmacology%20of%20effects%20of%20GLP-1-based%20therapies%20on%20gastric,%20biliary%20and%20intestinal%20motility&amp;author=RJ%20Jalleh&amp;author=CS%20Marathe&amp;author=CK%20Rayner&amp;author=KL%20Jones&amp;author=MM%20Umapathysivam&amp;volume=166&amp;publication_year=2024&amp;pages=bqae155&amp;pmid=39568409&amp;doi=10.1210/endocr/bqae155&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b24-dmj-2025-0242">
<span class="label">24.</span><cite>Orskov C, Poulsen SS, Moller M, Holst JJ. Glucagon-like peptide I receptors in the subfornical organ and the area postrema are accessible to circulating glucagon-like peptide I. Diabetes. 1996;45:832–5. doi: 10.2337/diab.45.6.832.</cite> [<a href="https://doi.org/10.2337/diab.45.6.832" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8635662/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes&amp;title=Glucagon-like%20peptide%20I%20receptors%20in%20the%20subfornical%20organ%20and%20the%20area%20postrema%20are%20accessible%20to%20circulating%20glucagon-like%20peptide%20I&amp;author=C%20Orskov&amp;author=SS%20Poulsen&amp;author=M%20Moller&amp;author=JJ%20Holst&amp;volume=45&amp;publication_year=1996&amp;pages=832-5&amp;pmid=8635662&amp;doi=10.2337/diab.45.6.832&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b25-dmj-2025-0242">
<span class="label">25.</span><cite>Amato A, Cinci L, Rotondo A, Serio R, Faussone-Pellegrini MS, Vannucchi MG, et al.  Peripheral motor action of glucagon-like peptide-1 through enteric neuronal receptors. Neurogastroenterol Motil. 2010;22:664–e203. doi: 10.1111/j.1365-2982.2010.01476.x.</cite> [<a href="https://doi.org/10.1111/j.1365-2982.2010.01476.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20158614/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Neurogastroenterol%20Motil&amp;title=Peripheral%20motor%20action%20of%20glucagon-like%20peptide-1%20through%20enteric%20neuronal%20receptors&amp;author=A%20Amato&amp;author=L%20Cinci&amp;author=A%20Rotondo&amp;author=R%20Serio&amp;author=MS%20Faussone-Pellegrini&amp;volume=22&amp;publication_year=2010&amp;pages=664-e203&amp;pmid=20158614&amp;doi=10.1111/j.1365-2982.2010.01476.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b26-dmj-2025-0242">
<span class="label">26.</span><cite>Tolessa T, Gutniak M, Holst JJ, Efendic S, Hellstrom PM. Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin. J Clin Invest. 1998;102:764–74. doi: 10.1172/JCI942.</cite> [<a href="https://doi.org/10.1172/JCI942" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC508939/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/9710445/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Invest&amp;title=Inhibitory%20effect%20of%20glucagon-like%20peptide-1%20on%20small%20bowel%20motility.%20Fasting%20but%20not%20fed%20motility%20inhibited%20via%20nitric%20oxide%20independently%20of%20insulin%20and%20somatostatin&amp;author=T%20Tolessa&amp;author=M%20Gutniak&amp;author=JJ%20Holst&amp;author=S%20Efendic&amp;author=PM%20Hellstrom&amp;volume=102&amp;publication_year=1998&amp;pages=764-74&amp;pmid=9710445&amp;doi=10.1172/JCI942&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b27-dmj-2025-0242">
<span class="label">27.</span><cite>Ushakumari DS, Sladen RN. ASA consensus-based guidance on preoperative management of patients on glucagon-like peptide-1 receptor agonists. Anesthesiology. 2024;140:346–8. doi: 10.1097/ALN.0000000000004776.</cite> [<a href="https://doi.org/10.1097/ALN.0000000000004776" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37982170/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Anesthesiology&amp;title=ASA%20consensus-based%20guidance%20on%20preoperative%20management%20of%20patients%20on%20glucagon-like%20peptide-1%20receptor%20agonists&amp;author=DS%20Ushakumari&amp;author=RN%20Sladen&amp;volume=140&amp;publication_year=2024&amp;pages=346-8&amp;pmid=37982170&amp;doi=10.1097/ALN.0000000000004776&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b28-dmj-2025-0242">
<span class="label">28.</span><cite>Hashash JG, Thompson CC, Wang AY. AGA rapid clinical practice update on the management of patients taking GLP-1 receptor agonists prior to endoscopy: communication. Clin Gastroenterol Hepatol. 2024;22:705–7. doi: 10.1016/j.cgh.2023.11.002.</cite> [<a href="https://doi.org/10.1016/j.cgh.2023.11.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37944573/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Gastroenterol%20Hepatol&amp;title=AGA%20rapid%20clinical%20practice%20update%20on%20the%20management%20of%20patients%20taking%20GLP-1%20receptor%20agonists%20prior%20to%20endoscopy:%20communication&amp;author=JG%20Hashash&amp;author=CC%20Thompson&amp;author=AY%20Wang&amp;volume=22&amp;publication_year=2024&amp;pages=705-7&amp;pmid=37944573&amp;doi=10.1016/j.cgh.2023.11.002&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b29-dmj-2025-0242">
<span class="label">29.</span><cite>Azoulay L, Filion KB, Platt RW, Dahl M, Dormuth CR, Clemens KK, et al.  Association between incretin-based drugs and the risk of acute pancreatitis. JAMA Intern Med. 2016;176:1464–73. doi: 10.1001/jamainternmed.2016.1522.</cite> [<a href="https://doi.org/10.1001/jamainternmed.2016.1522" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27479930/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Intern%20Med&amp;title=Association%20between%20incretin-based%20drugs%20and%20the%20risk%20of%20acute%20pancreatitis&amp;author=L%20Azoulay&amp;author=KB%20Filion&amp;author=RW%20Platt&amp;author=M%20Dahl&amp;author=CR%20Dormuth&amp;volume=176&amp;publication_year=2016&amp;pages=1464-73&amp;pmid=27479930&amp;doi=10.1001/jamainternmed.2016.1522&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b30-dmj-2025-0242">
<span class="label">30.</span><cite>Lundgren JR, Janus C, Jensen SB, Juhl CR, Olsen LM, Christensen RM, et al.  Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021;384:1719–30. doi: 10.1056/NEJMoa2028198.</cite> [<a href="https://doi.org/10.1056/NEJMoa2028198" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33951361/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Healthy%20weight%20loss%20maintenance%20with%20exercise,%20liraglutide,%20or%20both%20combined&amp;author=JR%20Lundgren&amp;author=C%20Janus&amp;author=SB%20Jensen&amp;author=CR%20Juhl&amp;author=LM%20Olsen&amp;volume=384&amp;publication_year=2021&amp;pages=1719-30&amp;pmid=33951361&amp;doi=10.1056/NEJMoa2028198&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b31-dmj-2025-0242">
<span class="label">31.</span><cite>Wadden TA, Bailey TS, Billings LK, Davies M, Frias JP, Koroleva A, et al.  Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325:1403–13. doi: 10.1001/jama.2021.1831.</cite> [<a href="https://doi.org/10.1001/jama.2021.1831" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7905697/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33625476/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA&amp;title=Effect%20of%20subcutaneous%20semaglutide%20vs%20placebo%20as%20an%20adjunct%20to%20intensive%20behavioral%20therapy%20on%20body%20weight%20in%20adults%20with%20overweight%20or%20obesity:%20the%20STEP%203%20randomized%20clinical%20trial&amp;author=TA%20Wadden&amp;author=TS%20Bailey&amp;author=LK%20Billings&amp;author=M%20Davies&amp;author=JP%20Frias&amp;volume=325&amp;publication_year=2021&amp;pages=1403-13&amp;pmid=33625476&amp;doi=10.1001/jama.2021.1831&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b32-dmj-2025-0242">
<span class="label">32.</span><cite>Wilding JP, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al.  Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002. doi: 10.1056/NEJMoa2032183.</cite> [<a href="https://doi.org/10.1056/NEJMoa2032183" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33567185/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Once-weekly%20semaglutide%20in%20adults%20with%20overweight%20or%20obesity&amp;author=JP%20Wilding&amp;author=RL%20Batterham&amp;author=S%20Calanna&amp;author=M%20Davies&amp;author=LF%20Van%20Gaal&amp;volume=384&amp;publication_year=2021&amp;pages=989-1002&amp;pmid=33567185&amp;doi=10.1056/NEJMoa2032183&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b33-dmj-2025-0242">
<span class="label">33.</span><cite>Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al.  Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–22. doi: 10.1056/NEJMoa1603827.</cite> [<a href="https://doi.org/10.1056/NEJMoa1603827" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4985288/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27295427/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Liraglutide%20and%20cardiovascular%20outcomes%20in%20type%202%20diabetes&amp;author=SP%20Marso&amp;author=GH%20Daniels&amp;author=K%20Brown-Frandsen&amp;author=P%20Kristensen&amp;author=JF%20Mann&amp;volume=375&amp;publication_year=2016&amp;pages=311-22&amp;pmid=27295427&amp;doi=10.1056/NEJMoa1603827&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b34-dmj-2025-0242">
<span class="label">34.</span><cite>Nauck MA, Muus Ghorbani ML, Kreiner E, Saevereid HA, Buse JB, LEADER Publication Committee on behalf of the LEADER Trial Investigators  Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial. Diabetes Care. 2019;42:1912–20. doi: 10.2337/dc19-0415.</cite> [<a href="https://doi.org/10.2337/dc19-0415" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7364668/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31399438/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&amp;title=Effects%20of%20liraglutide%20compared%20with%20placebo%20on%20events%20of%20acute%20gallbladder%20or%20biliary%20disease%20in%20patients%20with%20type%202%20diabetes%20at%20high%20risk%20for%20cardiovascular%20events%20in%20the%20LEADER%20randomized%20trial&amp;author=MA%20Nauck&amp;author=ML%20Muus%20Ghorbani&amp;author=E%20Kreiner&amp;author=HA%20Saevereid&amp;author=JB%20Buse&amp;volume=42&amp;publication_year=2019&amp;pages=1912-20&amp;pmid=31399438&amp;doi=10.2337/dc19-0415&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b35-dmj-2025-0242">
<span class="label">35.</span><cite>Faillie JL, Yu OH, Yin H, Hillaire-Buys D, Barkun A, Azoulay L. Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus. JAMA Intern Med. 2016;176:1474–81. doi: 10.1001/jamainternmed.2016.1531.</cite> [<a href="https://doi.org/10.1001/jamainternmed.2016.1531" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27478902/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Intern%20Med&amp;title=Association%20of%20bile%20duct%20and%20gallbladder%20diseases%20with%20the%20use%20of%20incretin-based%20drugs%20in%20patients%20with%20type%202%20diabetes%20mellitus&amp;author=JL%20Faillie&amp;author=OH%20Yu&amp;author=H%20Yin&amp;author=D%20Hillaire-Buys&amp;author=A%20Barkun&amp;volume=176&amp;publication_year=2016&amp;pages=1474-81&amp;pmid=27478902&amp;doi=10.1001/jamainternmed.2016.1531&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b36-dmj-2025-0242">
<span class="label">36.</span><cite>Dong YH, Wu JH, Chang CH, Lin JW, Wu LC, Toh S. Association between glucagon-like peptide-1 receptor agonists and biliary-related diseases in patients with type 2 diabetes: a nationwide cohort study. Pharmacotherapy. 2022;42:483–94. doi: 10.1002/phar.2688.</cite> [<a href="https://doi.org/10.1002/phar.2688" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35508702/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pharmacotherapy&amp;title=Association%20between%20glucagon-like%20peptide-1%20receptor%20agonists%20and%20biliary-related%20diseases%20in%20patients%20with%20type%202%20diabetes:%20a%20nationwide%20cohort%20study&amp;author=YH%20Dong&amp;author=JH%20Wu&amp;author=CH%20Chang&amp;author=JW%20Lin&amp;author=LC%20Wu&amp;volume=42&amp;publication_year=2022&amp;pages=483-94&amp;pmid=35508702&amp;doi=10.1002/phar.2688&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b37-dmj-2025-0242">
<span class="label">37.</span><cite>Madsbad S. Review of head-to-head comparisons of glucagon-like peptide-1 receptor agonists. Diabetes Obes Metab. 2016;18:317–32. doi: 10.1111/dom.12596.</cite> [<a href="https://doi.org/10.1111/dom.12596" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5064617/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26511102/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Obes%20Metab&amp;title=Review%20of%20head-to-head%20comparisons%20of%20glucagon-like%20peptide-1%20receptor%20agonists&amp;author=S%20Madsbad&amp;volume=18&amp;publication_year=2016&amp;pages=317-32&amp;pmid=26511102&amp;doi=10.1111/dom.12596&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b38-dmj-2025-0242">
<span class="label">38.</span><cite>Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al.  Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121–30. doi: 10.1016/S0140-6736(19)31149-3.</cite> [<a href="https://doi.org/10.1016/S0140-6736(19)31149-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31189511/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Dulaglutide%20and%20cardiovascular%20outcomes%20in%20type%202%20diabetes%20(REWIND):%20a%20double-blind,%20randomised%20placebo-controlled%20trial&amp;author=HC%20Gerstein&amp;author=HM%20Colhoun&amp;author=GR%20Dagenais&amp;author=R%20Diaz&amp;author=M%20Lakshmanan&amp;volume=394&amp;publication_year=2019&amp;pages=121-30&amp;pmid=31189511&amp;doi=10.1016/S0140-6736(19)31149-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b39-dmj-2025-0242">
<span class="label">39.</span><cite>He L, Wang J, Ping F, Yang N, Huang J, Li Y, et al.  Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022;182:513–9. doi: 10.1001/jamainternmed.2022.0338.</cite> [<a href="https://doi.org/10.1001/jamainternmed.2022.0338" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8961394/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35344001/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Intern%20Med&amp;title=Association%20of%20glucagon-like%20peptide-1%20receptor%20agonist%20use%20with%20risk%20of%20gallbladder%20and%20biliary%20diseases:%20a%20systematic%20review%20and%20meta-analysis%20of%20randomized%20clinical%20trials&amp;author=L%20He&amp;author=J%20Wang&amp;author=F%20Ping&amp;author=N%20Yang&amp;author=J%20Huang&amp;volume=182&amp;publication_year=2022&amp;pages=513-9&amp;pmid=35344001&amp;doi=10.1001/jamainternmed.2022.0338&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b40-dmj-2025-0242">
<span class="label">40.</span><cite>Erlinger S. Gallstones in obesity and weight loss. Eur J Gastroenterol Hepatol. 2000;12:1347–52. doi: 10.1097/00042737-200012120-00015.</cite> [<a href="https://doi.org/10.1097/00042737-200012120-00015" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11192327/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Eur%20J%20Gastroenterol%20Hepatol&amp;title=Gallstones%20in%20obesity%20and%20weight%20loss&amp;author=S%20Erlinger&amp;volume=12&amp;publication_year=2000&amp;pages=1347-52&amp;pmid=11192327&amp;doi=10.1097/00042737-200012120-00015&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b41-dmj-2025-0242">
<span class="label">41.</span><cite>Gether IM, Nexoe-Larsen C, Knop FK. New avenues in the regulation of gallbladder motility-implications for the use of glucagon-like peptide-derived drugs. J Clin Endocrinol Metab. 2019;104:2463–72. doi: 10.1210/jc.2018-01008.</cite> [<a href="https://doi.org/10.1210/jc.2018-01008" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30137354/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Endocrinol%20Metab&amp;title=New%20avenues%20in%20the%20regulation%20of%20gallbladder%20motility-implications%20for%20the%20use%20of%20glucagon-like%20peptide-derived%20drugs&amp;author=IM%20Gether&amp;author=C%20Nexoe-Larsen&amp;author=FK%20Knop&amp;volume=104&amp;publication_year=2019&amp;pages=2463-72&amp;pmid=30137354&amp;doi=10.1210/jc.2018-01008&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b42-dmj-2025-0242">
<span class="label">42.</span><cite>Nexoe-Larsen CC, Sorensen PH, Hausner H, Agersnap M, Baekdal M, Bronden A, et al.  Effects of liraglutide on gallbladder emptying: a randomized, placebo-controlled trial in adults with overweight or obesity. Diabetes Obes Metab. 2018;20:2557–64. doi: 10.1111/dom.13420.</cite> [<a href="https://doi.org/10.1111/dom.13420" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6220792/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29892986/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Obes%20Metab&amp;title=Effects%20of%20liraglutide%20on%20gallbladder%20emptying:%20a%20randomized,%20placebo-controlled%20trial%20in%20adults%20with%20overweight%20or%20obesity&amp;author=CC%20Nexoe-Larsen&amp;author=PH%20Sorensen&amp;author=H%20Hausner&amp;author=M%20Agersnap&amp;author=M%20Baekdal&amp;volume=20&amp;publication_year=2018&amp;pages=2557-64&amp;pmid=29892986&amp;doi=10.1111/dom.13420&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b43-dmj-2025-0242">
<span class="label">43.</span><cite>Rehfeld JF, Knop FK, Asmar A, Madsbad S, Holst JJ, Asmar M. Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. Scand J Gastroenterol. 2018;53:1429–32. doi: 10.1080/00365521.2018.1530297.</cite> [<a href="https://doi.org/10.1080/00365521.2018.1530297" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30449207/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Scand%20J%20Gastroenterol&amp;title=Cholecystokinin%20secretion%20is%20suppressed%20by%20glucagon-like%20peptide-1:%20clue%20to%20the%20mechanism%20of%20the%20adverse%20gallbladder%20events%20of%20GLP-1-derived%20drugs&amp;author=JF%20Rehfeld&amp;author=FK%20Knop&amp;author=A%20Asmar&amp;author=S%20Madsbad&amp;author=JJ%20Holst&amp;volume=53&amp;publication_year=2018&amp;pages=1429-32&amp;pmid=30449207&amp;doi=10.1080/00365521.2018.1530297&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b44-dmj-2025-0242">
<span class="label">44.</span><cite>Shaddinger BC, Young MA, Billiard J, Collins DA, Hussaini A, Nino A. Effect of albiglutide on cholecystokinin-induced gallbladder emptying in healthy individuals: a randomized crossover study. J Clin Pharmacol. 2017;57:1322–9. doi: 10.1002/jcph.940.</cite> [<a href="https://doi.org/10.1002/jcph.940" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28543352/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Pharmacol&amp;title=Effect%20of%20albiglutide%20on%20cholecystokinin-induced%20gallbladder%20emptying%20in%20healthy%20individuals:%20a%20randomized%20crossover%20study&amp;author=BC%20Shaddinger&amp;author=MA%20Young&amp;author=J%20Billiard&amp;author=DA%20Collins&amp;author=A%20Hussaini&amp;volume=57&amp;publication_year=2017&amp;pages=1322-9&amp;pmid=28543352&amp;doi=10.1002/jcph.940&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b45-dmj-2025-0242">
<span class="label">45.</span><cite>Keller J, Trautmann ME, Haber H, Tham LS, Hunt T, Mace K, et al.  Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects. Regul Pept. 2012;179:77–83. doi: 10.1016/j.regpep.2012.08.005.</cite> [<a href="https://doi.org/10.1016/j.regpep.2012.08.005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22960288/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Regul%20Pept&amp;title=Effect%20of%20exenatide%20on%20cholecystokinin-induced%20gallbladder%20emptying%20in%20fasting%20healthy%20subjects&amp;author=J%20Keller&amp;author=ME%20Trautmann&amp;author=H%20Haber&amp;author=LS%20Tham&amp;author=T%20Hunt&amp;volume=179&amp;publication_year=2012&amp;pages=77-83&amp;pmid=22960288&amp;doi=10.1016/j.regpep.2012.08.005&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b46-dmj-2025-0242">
<span class="label">46.</span><cite>Njeze GE. Gallstones. Niger J Surg. 2013;19:49–55. doi: 10.4103/1117-6806.119236.</cite> [<a href="https://doi.org/10.4103/1117-6806.119236" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3899548/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24497751/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Niger%20J%20Surg&amp;title=Gallstones&amp;author=GE%20Njeze&amp;volume=19&amp;publication_year=2013&amp;pages=49-55&amp;pmid=24497751&amp;doi=10.4103/1117-6806.119236&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b47-dmj-2025-0242">
<span class="label">47.</span><cite>Marzioni M, Alpini G, Saccomanno S, Candelaresi C, Venter J, Rychlicki C, et al.  Glucagon-like peptide-1 and its receptor agonist exendin-4 modulate cholangiocyte adaptive response to cholestasis. Gastroenterology. 2007;133:244–55. doi: 10.1053/j.gastro.2007.04.007.</cite> [<a href="https://doi.org/10.1053/j.gastro.2007.04.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17631146/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterology&amp;title=Glucagon-like%20peptide-1%20and%20its%20receptor%20agonist%20exendin-4%20modulate%20cholangiocyte%20adaptive%20response%20to%20cholestasis&amp;author=M%20Marzioni&amp;author=G%20Alpini&amp;author=S%20Saccomanno&amp;author=C%20Candelaresi&amp;author=J%20Venter&amp;volume=133&amp;publication_year=2007&amp;pages=244-55&amp;pmid=17631146&amp;doi=10.1053/j.gastro.2007.04.007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b48-dmj-2025-0242">
<span class="label">48.</span><cite>Marzioni M, Alpini G, Saccomanno S, Candelaresi C, Venter J, Rychlicki C, et al.  Exendin-4, a glucagon-like peptide 1 receptor agonist, protects cholangiocytes from apoptosis. Gut. 2009;58:990–7. doi: 10.1136/gut.2008.150870.</cite> [<a href="https://doi.org/10.1136/gut.2008.150870" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2695839/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18829977/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gut&amp;title=Exendin-4,%20a%20glucagon-like%20peptide%201%20receptor%20agonist,%20protects%20cholangiocytes%20from%20apoptosis&amp;author=M%20Marzioni&amp;author=G%20Alpini&amp;author=S%20Saccomanno&amp;author=C%20Candelaresi&amp;author=J%20Venter&amp;volume=58&amp;publication_year=2009&amp;pages=990-7&amp;pmid=18829977&amp;doi=10.1136/gut.2008.150870&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b49-dmj-2025-0242">
<span class="label">49.</span><cite>Gorgojo-Martinez JJ, Mezquita-Raya P, Carretero-Gomez J, Castro A, Cebrian-Cuenca A, de Torres-Sanchez A, et al.  Clinical recommendations to manage gastrointestinal adverse events in patients treated with Glp-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2022;12:145. doi: 10.3390/jcm12010145.</cite> [<a href="https://doi.org/10.3390/jcm12010145" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9821052/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36614945/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Med&amp;title=Clinical%20recommendations%20to%20manage%20gastrointestinal%20adverse%20events%20in%20patients%20treated%20with%20Glp-1%20receptor%20agonists:%20a%20multidisciplinary%20expert%20consensus&amp;author=JJ%20Gorgojo-Martinez&amp;author=P%20Mezquita-Raya&amp;author=J%20Carretero-Gomez&amp;author=A%20Castro&amp;author=A%20Cebrian-Cuenca&amp;volume=12&amp;publication_year=2022&amp;pages=145&amp;pmid=36614945&amp;doi=10.3390/jcm12010145&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b50-dmj-2025-0242">
<span class="label">50.</span><cite>Denker PS, Dimarco PE. Exenatide (exendin-4)-induced pancreatitis: a case report. Diabetes Care. 2006;29:471. doi: 10.2337/diacare.29.02.06.dc05-2043.</cite> [<a href="https://doi.org/10.2337/diacare.29.02.06.dc05-2043" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16443920/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&amp;title=Exenatide%20(exendin-4)-induced%20pancreatitis:%20a%20case%20report&amp;author=PS%20Denker&amp;author=PE%20Dimarco&amp;volume=29&amp;publication_year=2006&amp;pages=471&amp;pmid=16443920&amp;doi=10.2337/diacare.29.02.06.dc05-2043&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b51-dmj-2025-0242">
<span class="label">51.</span><cite>Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. Gastroenterology. 2011;141:150–6. doi: 10.1053/j.gastro.2011.02.018.</cite> [<a href="https://doi.org/10.1053/j.gastro.2011.02.018" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4404515/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21334333/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Gastroenterology&amp;title=Pancreatitis,%20pancreatic,%20and%20thyroid%20cancer%20with%20glucagon-like%20peptide-1-based%20therapies&amp;author=M%20Elashoff&amp;author=AV%20Matveyenko&amp;author=B%20Gier&amp;author=R%20Elashoff&amp;author=PC%20Butler&amp;volume=141&amp;publication_year=2011&amp;pages=150-6&amp;pmid=21334333&amp;doi=10.1053/j.gastro.2011.02.018&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b52-dmj-2025-0242">
<span class="label">52.</span><cite>Yang Z, Lv Y, Yu M, Mei M, Xiang L, Zhao S, et al.  GLP-1 receptor agonist-associated tumor adverse events: a real-world study from 2004 to 2021 based on FAERS. Front Pharmacol. 2022;13:925377. doi: 10.3389/fphar.2022.925377.</cite> [<a href="https://doi.org/10.3389/fphar.2022.925377" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9640975/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36386208/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Pharmacol&amp;title=GLP-1%20receptor%20agonist-associated%20tumor%20adverse%20events:%20a%20real-world%20study%20from%202004%20to%202021%20based%20on%20FAERS&amp;author=Z%20Yang&amp;author=Y%20Lv&amp;author=M%20Yu&amp;author=M%20Mei&amp;author=L%20Xiang&amp;volume=13&amp;publication_year=2022&amp;pages=925377&amp;pmid=36386208&amp;doi=10.3389/fphar.2022.925377&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b53-dmj-2025-0242">
<span class="label">53.</span><cite>Abd El Aziz M, Cahyadi O, Meier JJ, Schmidt WE, Nauck MA. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diabetes Obes Metab. 2020;22:699–704. doi: 10.1111/dom.13924.</cite> [<a href="https://doi.org/10.1111/dom.13924" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31750601/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Obes%20Metab&amp;title=Incretin-based%20glucose-lowering%20medications%20and%20the%20risk%20of%20acute%20pancreatitis%20and%20malignancies:%20a%20meta-analysis%20based%20on%20cardiovascular%20outcomes%20trials&amp;author=M%20Abd%20El%20Aziz&amp;author=O%20Cahyadi&amp;author=JJ%20Meier&amp;author=WE%20Schmidt&amp;author=MA%20Nauck&amp;volume=22&amp;publication_year=2020&amp;pages=699-704&amp;pmid=31750601&amp;doi=10.1111/dom.13924&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b54-dmj-2025-0242">
<span class="label">54.</span><cite>Nauck MA, Frossard JL, Barkin JS, Anglin G, Hensley IE, Harper KD, et al.  Assessment of pancreas safety in the development program of once-weekly GLP-1 receptor agonist dulaglutide. Diabetes Care. 2017;40:647–54. doi: 10.2337/dc16-0984.</cite> [<a href="https://doi.org/10.2337/dc16-0984" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28283565/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&amp;title=Assessment%20of%20pancreas%20safety%20in%20the%20development%20program%20of%20once-weekly%20GLP-1%20receptor%20agonist%20dulaglutide&amp;author=MA%20Nauck&amp;author=JL%20Frossard&amp;author=JS%20Barkin&amp;author=G%20Anglin&amp;author=IE%20Hensley&amp;volume=40&amp;publication_year=2017&amp;pages=647-54&amp;pmid=28283565&amp;doi=10.2337/dc16-0984&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b55-dmj-2025-0242">
<span class="label">55.</span><cite>Azoulay L, Filion KB, Platt RW, Dahl M, Dormuth CR, Clemens KK, et al.  Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study. BMJ. 2016;352:i581. doi: 10.1136/bmj.i581.</cite> [<a href="https://doi.org/10.1136/bmj.i581" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4772785/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26888382/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMJ&amp;title=Incretin%20based%20drugs%20and%20the%20risk%20of%20pancreatic%20cancer:%20international%20multicentre%20cohort%20study&amp;author=L%20Azoulay&amp;author=KB%20Filion&amp;author=RW%20Platt&amp;author=M%20Dahl&amp;author=CR%20Dormuth&amp;volume=352&amp;publication_year=2016&amp;pages=i581&amp;pmid=26888382&amp;doi=10.1136/bmj.i581&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b56-dmj-2025-0242">
<span class="label">56.</span><cite>Wilhite K, Reid JM, Lane M. Risk of pancreatitis with incretin therapies versus thiazolidinediones in the Veterans Health Administration. Ann Pharmacother. 2024;58:685–9. doi: 10.1177/10600280231205490.</cite> [<a href="https://doi.org/10.1177/10600280231205490" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37881914/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Pharmacother&amp;title=Risk%20of%20pancreatitis%20with%20incretin%20therapies%20versus%20thiazolidinediones%20in%20the%20Veterans%20Health%20Administration&amp;author=K%20Wilhite&amp;author=JM%20Reid&amp;author=M%20Lane&amp;volume=58&amp;publication_year=2024&amp;pages=685-9&amp;pmid=37881914&amp;doi=10.1177/10600280231205490&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b57-dmj-2025-0242">
<span class="label">57.</span><cite>Shihab HM, Akande T, Armstrong K, Singh S, Loke YK. Risk of pancreatic adverse events associated with the use of glucagon-like peptide-1 receptor agonist and dipeptidyl peptidase-4 inhibitor drugs: a systematic review and meta-analysis of randomized trials. World J Metaanal. 2015;3:254–83.</cite> [<a href="https://scholar.google.com/scholar_lookup?journal=World%20J%20Metaanal&amp;title=Risk%20of%20pancreatic%20adverse%20events%20associated%20with%20the%20use%20of%20glucagon-like%20peptide-1%20receptor%20agonist%20and%20dipeptidyl%20peptidase-4%20inhibitor%20drugs:%20a%20systematic%20review%20and%20meta-analysis%20of%20randomized%20trials&amp;author=HM%20Shihab&amp;author=T%20Akande&amp;author=K%20Armstrong&amp;author=S%20Singh&amp;author=YK%20Loke&amp;volume=3&amp;publication_year=2015&amp;pages=254-83&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b58-dmj-2025-0242">
<span class="label">58.</span><cite>Monami M, Nreu B, Scatena A, Cresci B, Andreozzi F, Sesti G, et al.  Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): data from randomized controlled trials. Diabetes Obes Metab. 2017;19:1233–41. doi: 10.1111/dom.12926.</cite> [<a href="https://doi.org/10.1111/dom.12926" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28244632/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Obes%20Metab&amp;title=Safety%20issues%20with%20glucagon-like%20peptide-1%20receptor%20agonists%20(pancreatitis,%20pancreatic%20cancer%20and%20cholelithiasis):%20data%20from%20randomized%20controlled%20trials&amp;author=M%20Monami&amp;author=B%20Nreu&amp;author=A%20Scatena&amp;author=B%20Cresci&amp;author=F%20Andreozzi&amp;volume=19&amp;publication_year=2017&amp;pages=1233-41&amp;pmid=28244632&amp;doi=10.1111/dom.12926&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b59-dmj-2025-0242">
<span class="label">59.</span><cite>Singh S, Chang HY, Richards TM, Weiner JP, Clark JM, Segal JB. Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Intern Med. 2013;173:534–9. doi: 10.1001/jamainternmed.2013.2720.</cite> [<a href="https://doi.org/10.1001/jamainternmed.2013.2720" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23440284/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Intern%20Med&amp;title=Glucagonlike%20peptide%201-based%20therapies%20and%20risk%20of%20hospitalization%20for%20acute%20pancreatitis%20in%20type%202%20diabetes%20mellitus:%20a%20population-based%20matched%20case-control%20study&amp;author=S%20Singh&amp;author=HY%20Chang&amp;author=TM%20Richards&amp;author=JP%20Weiner&amp;author=JM%20Clark&amp;volume=173&amp;publication_year=2013&amp;pages=534-9&amp;pmid=23440284&amp;doi=10.1001/jamainternmed.2013.2720&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b60-dmj-2025-0242">
<span class="label">60.</span><cite>Dankner R, Murad H, Agay N, Olmer L, Freedman LS. Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk in patients with type 2 diabetes. JAMA Netw Open. 2024;7:e2350408.  doi: 10.1001/jamanetworkopen.2023.50408.</cite> [<a href="https://doi.org/10.1001/jamanetworkopen.2023.50408" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10767614/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38175642/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Netw%20Open&amp;title=Glucagon-like%20peptide-1%20receptor%20agonists%20and%20pancreatic%20cancer%20risk%20in%20patients%20with%20type%202%20diabetes&amp;author=R%20Dankner&amp;author=H%20Murad&amp;author=N%20Agay&amp;author=L%20Olmer&amp;author=LS%20Freedman&amp;volume=7&amp;publication_year=2024&amp;pages=e2350408&amp;pmid=38175642&amp;doi=10.1001/jamanetworkopen.2023.50408&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b61-dmj-2025-0242">
<span class="label">61.</span><cite>Wang L, Wang Q, Li L, Kaelber DC, Xu R. Glucagon-like peptide-1 receptor agonists and pancreatic cancer risk: target trial emulation using real-world data. J Natl Cancer Inst. 2025;117:476–85. doi: 10.1093/jnci/djae260.</cite> [<a href="https://doi.org/10.1093/jnci/djae260" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11884861/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39418202/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Natl%20Cancer%20Inst&amp;title=Glucagon-like%20peptide-1%20receptor%20agonists%20and%20pancreatic%20cancer%20risk:%20target%20trial%20emulation%20using%20real-world%20data&amp;author=L%20Wang&amp;author=Q%20Wang&amp;author=L%20Li&amp;author=DC%20Kaelber&amp;author=R%20Xu&amp;volume=117&amp;publication_year=2025&amp;pages=476-85&amp;pmid=39418202&amp;doi=10.1093/jnci/djae260&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b62-dmj-2025-0242">
<span class="label">62.</span><cite>Tatarkiewicz K, Belanger P, Gu G, Parkes D, Roy D. No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks. Diabetes Obes Metab. 2013;15:417–26. doi: 10.1111/dom.12040.</cite> [<a href="https://doi.org/10.1111/dom.12040" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3654567/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23163898/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Obes%20Metab&amp;title=No%20evidence%20of%20drug-induced%20pancreatitis%20in%20rats%20treated%20with%20exenatide%20for%2013%20weeks&amp;author=K%20Tatarkiewicz&amp;author=P%20Belanger&amp;author=G%20Gu&amp;author=D%20Parkes&amp;author=D%20Roy&amp;volume=15&amp;publication_year=2013&amp;pages=417-26&amp;pmid=23163898&amp;doi=10.1111/dom.12040&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b63-dmj-2025-0242">
<span class="label">63.</span><cite>Vrang N, Jelsing J, Simonsen L, Jensen AE, Thorup I, Soeborg H, et al.  The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis. Am J Physiol Endocrinol Metab. 2012;303:E253–64. doi: 10.1152/ajpendo.00182.2012.</cite> [<a href="https://doi.org/10.1152/ajpendo.00182.2012" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22589391/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Physiol%20Endocrinol%20Metab&amp;title=The%20effects%20of%2013%20wk%20of%20liraglutide%20treatment%20on%20endocrine%20and%20exocrine%20pancreas%20in%20male%20and%20female%20ZDF%20rats:%20a%20quantitative%20and%20qualitative%20analysis%20revealing%20no%20evidence%20of%20drug-induced%20pancreatitis&amp;author=N%20Vrang&amp;author=J%20Jelsing&amp;author=L%20Simonsen&amp;author=AE%20Jensen&amp;author=I%20Thorup&amp;volume=303&amp;publication_year=2012&amp;pages=E253-64&amp;pmid=22589391&amp;doi=10.1152/ajpendo.00182.2012&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b64-dmj-2025-0242">
<span class="label">64.</span><cite>Gier B, Matveyenko AV, Kirakossian D, Dawson D, Dry SM, Butler PC. Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model. Diabetes. 2012;61:1250–62. doi: 10.2337/db11-1109.</cite> [<a href="https://doi.org/10.2337/db11-1109" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3331736/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22266668/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes&amp;title=Chronic%20GLP-1%20receptor%20activation%20by%20exendin-4%20induces%20expansion%20of%20pancreatic%20duct%20glands%20in%20rats%20and%20accelerates%20formation%20of%20dysplastic%20lesions%20and%20chronic%20pancreatitis%20in%20the%20Kras(G12D)%20mouse%20model&amp;author=B%20Gier&amp;author=AV%20Matveyenko&amp;author=D%20Kirakossian&amp;author=D%20Dawson&amp;author=SM%20Dry&amp;volume=61&amp;publication_year=2012&amp;pages=1250-62&amp;pmid=22266668&amp;doi=10.2337/db11-1109&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b65-dmj-2025-0242">
<span class="label">65.</span><cite>Chis BA, Fodor D. Acute pancreatitis during GLP-1 receptor agonist treatment: a case report. Clujul Med. 2018;91:117–9. doi: 10.15386/cjmed-804.</cite> [<a href="https://doi.org/10.15386/cjmed-804" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5808258/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29440961/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clujul%20Med&amp;title=Acute%20pancreatitis%20during%20GLP-1%20receptor%20agonist%20treatment:%20a%20case%20report&amp;author=BA%20Chis&amp;author=D%20Fodor&amp;volume=91&amp;publication_year=2018&amp;pages=117-9&amp;pmid=29440961&amp;doi=10.15386/cjmed-804&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b66-dmj-2025-0242">
<span class="label">66.</span><cite>Leutner M, Dervic E, Bellach L, Klimek P, Thurner S, Kautzky A. Obesity as pleiotropic risk state for metabolic and mental health throughout life. Transl Psychiatry. 2023;13:175. doi: 10.1038/s41398-023-02447-w.</cite> [<a href="https://doi.org/10.1038/s41398-023-02447-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10227059/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37248222/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Transl%20Psychiatry&amp;title=Obesity%20as%20pleiotropic%20risk%20state%20for%20metabolic%20and%20mental%20health%20throughout%20life&amp;author=M%20Leutner&amp;author=E%20Dervic&amp;author=L%20Bellach&amp;author=P%20Klimek&amp;author=S%20Thurner&amp;volume=13&amp;publication_year=2023&amp;pages=175&amp;pmid=37248222&amp;doi=10.1038/s41398-023-02447-w&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b67-dmj-2025-0242">
<span class="label">67.</span><cite>Coulter AA, Rebello CJ, Greenway FL. Centrally acting agents for obesity: past, present, and future. Drugs. 2018;78:1113–32. doi: 10.1007/s40265-018-0946-y.</cite> [<a href="https://doi.org/10.1007/s40265-018-0946-y" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6095132/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30014268/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Drugs&amp;title=Centrally%20acting%20agents%20for%20obesity:%20past,%20present,%20and%20future&amp;author=AA%20Coulter&amp;author=CJ%20Rebello&amp;author=FL%20Greenway&amp;volume=78&amp;publication_year=2018&amp;pages=1113-32&amp;pmid=30014268&amp;doi=10.1007/s40265-018-0946-y&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b68-dmj-2025-0242">
<span class="label">68.</span><cite>Kornelius E, Huang JY, Lo SC, Huang CN, Yang YS. The risk of depression, anxiety, and suicidal behavior in patients with obesity on glucagon like peptide-1 receptor agonist therapy. Sci Rep. 2024;14:24433. doi: 10.1038/s41598-024-75965-2.</cite> [<a href="https://doi.org/10.1038/s41598-024-75965-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11489776/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39424950/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sci%20Rep&amp;title=The%20risk%20of%20depression,%20anxiety,%20and%20suicidal%20behavior%20in%20patients%20with%20obesity%20on%20glucagon%20like%20peptide-1%20receptor%20agonist%20therapy&amp;author=E%20Kornelius&amp;author=JY%20Huang&amp;author=SC%20Lo&amp;author=CN%20Huang&amp;author=YS%20Yang&amp;volume=14&amp;publication_year=2024&amp;pages=24433&amp;pmid=39424950&amp;doi=10.1038/s41598-024-75965-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b69-dmj-2025-0242">
<span class="label">69.</span><cite>Shettar V, Patel S, Kidambi S. Epidemiology of obesity and pharmacologic treatment options. Nutr Clin Pract. 2017;32:441–62. doi: 10.1177/0884533617713189.</cite> [<a href="https://doi.org/10.1177/0884533617713189" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28632997/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nutr%20Clin%20Pract&amp;title=Epidemiology%20of%20obesity%20and%20pharmacologic%20treatment%20options&amp;author=V%20Shettar&amp;author=S%20Patel&amp;author=S%20Kidambi&amp;volume=32&amp;publication_year=2017&amp;pages=441-62&amp;pmid=28632997&amp;doi=10.1177/0884533617713189&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b70-dmj-2025-0242">
<span class="label">70.</span><cite>Sam AH, Salem V, Ghatei MA. Rimonabant: from RIO to ban. J Obes. 2011;2011:432607. doi: 10.1155/2011/432607.</cite> [<a href="https://doi.org/10.1155/2011/432607" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3136184/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21773005/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Obes&amp;title=Rimonabant:%20from%20RIO%20to%20ban&amp;author=AH%20Sam&amp;author=V%20Salem&amp;author=MA%20Ghatei&amp;volume=2011&amp;publication_year=2011&amp;pages=432607&amp;pmid=21773005&amp;doi=10.1155/2011/432607&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b71-dmj-2025-0242">
<span class="label">71.</span><cite>O’Neil PM, Aroda VR, Astrup A, Kushner R, Lau DC, Wadden TA, et al.  Neuropsychiatric safety with liraglutide 3.0 mg for weight management: results from randomized controlled phase 2 and 3a trials. Diabetes Obes Metab. 2017;19:1529–36. doi: 10.1111/dom.12963.</cite> [<a href="https://doi.org/10.1111/dom.12963" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5655710/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28386912/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Obes%20Metab&amp;title=Neuropsychiatric%20safety%20with%20liraglutide%203.0%20mg%20for%20weight%20management:%20results%20from%20randomized%20controlled%20phase%202%20and%203a%20trials&amp;author=PM%20O%E2%80%99Neil&amp;author=VR%20Aroda&amp;author=A%20Astrup&amp;author=R%20Kushner&amp;author=DC%20Lau&amp;volume=19&amp;publication_year=2017&amp;pages=1529-36&amp;pmid=28386912&amp;doi=10.1111/dom.12963&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b72-dmj-2025-0242">
<span class="label">72.</span><cite> European Medicines Agency. EMA statement on ongoing review of GLP-1 receptor agonists. Available from:  <a href="https://www.ema.europa.eu/en/news/ema-statement-ongoing-review-glp-1-receptor-agonists" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">www.ema.europa.eu/en/news/ema-statement-ongoing-review-glp-1-receptor-agonists</a> (cited 2025 Jun 11)</cite>
</li>
<li id="b73-dmj-2025-0242">
<span class="label">73.</span><cite>Schoretsanitis G, Weiler S, Barbui C, Raschi E, Gastaldon C. Disproportionality analysis from World Health Organization data on semaglutide, liraglutide, and suicidality. JAMA Netw Open. 2024;7:e2423385.  doi: 10.1001/jamanetworkopen.2024.23385.</cite> [<a href="https://doi.org/10.1001/jamanetworkopen.2024.23385" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11337067/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39163046/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Netw%20Open&amp;title=Disproportionality%20analysis%20from%20World%20Health%20Organization%20data%20on%20semaglutide,%20liraglutide,%20and%20suicidality&amp;author=G%20Schoretsanitis&amp;author=S%20Weiler&amp;author=C%20Barbui&amp;author=E%20Raschi&amp;author=C%20Gastaldon&amp;volume=7&amp;publication_year=2024&amp;pages=e2423385&amp;pmid=39163046&amp;doi=10.1001/jamanetworkopen.2024.23385&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b74-dmj-2025-0242">
<span class="label">74.</span><cite>McIntyre RS, Mansur RB, Rosenblat JD, Kwan AT. The association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: reports to the Food and Drug Administration Adverse Event Reporting System (FAERS) Expert Opin Drug Saf. 2024;23:47–55. doi: 10.1080/14740338.2023.2295397.</cite> [<a href="https://doi.org/10.1080/14740338.2023.2295397" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38087976/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Expert%20Opin%20Drug%20Saf&amp;title=The%20association%20between%20glucagon-like%20peptide-1%20receptor%20agonists%20(GLP-1%20RAs)%20and%20suicidality:%20reports%20to%20the%20Food%20and%20Drug%20Administration%20Adverse%20Event%20Reporting%20System%20(FAERS)&amp;author=RS%20McIntyre&amp;author=RB%20Mansur&amp;author=JD%20Rosenblat&amp;author=AT%20Kwan&amp;volume=23&amp;publication_year=2024&amp;pages=47-55&amp;pmid=38087976&amp;doi=10.1080/14740338.2023.2295397&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b75-dmj-2025-0242">
<span class="label">75.</span><cite>Wadden TA, Brown GK, Egebjerg C, Frenkel O, Goldman B, Kushner RF, et al.  Psychiatric safety of semaglutide for weight management in people without known major psychopathology: post hoc analysis of the STEP 1, 2, 3, and 5 Trials. JAMA Intern Med. 2024;184:1290–300. doi: 10.1001/jamainternmed.2024.4346.</cite> [<a href="https://doi.org/10.1001/jamainternmed.2024.4346" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11372653/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39226070/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Intern%20Med&amp;title=Psychiatric%20safety%20of%20semaglutide%20for%20weight%20management%20in%20people%20without%20known%20major%20psychopathology:%20post%20hoc%20analysis%20of%20the%20STEP%201,%202,%203,%20and%205%20Trials&amp;author=TA%20Wadden&amp;author=GK%20Brown&amp;author=C%20Egebjerg&amp;author=O%20Frenkel&amp;author=B%20Goldman&amp;volume=184&amp;publication_year=2024&amp;pages=1290-300&amp;pmid=39226070&amp;doi=10.1001/jamainternmed.2024.4346&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b76-dmj-2025-0242">
<span class="label">76.</span><cite>Hurtado I, Robles C, Peiro S, Garcia-Sempere A, Sanfelix-Gimeno G. Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study. Diabetologia. 2024;67:2471–80. doi: 10.1007/s00125-024-06243-z.</cite> [<a href="https://doi.org/10.1007/s00125-024-06243-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11519213/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39103719/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetologia&amp;title=Association%20of%20glucagon-like%20peptide-1%20receptor%20agonists%20with%20suicidal%20ideation%20and%20self-injury%20in%20individuals%20with%20diabetes%20and%20obesity:%20a%20propensity-weighted,%20population-based%20cohort%20study&amp;author=I%20Hurtado&amp;author=C%20Robles&amp;author=S%20Peiro&amp;author=A%20Garcia-Sempere&amp;author=G%20Sanfelix-Gimeno&amp;volume=67&amp;publication_year=2024&amp;pages=2471-80&amp;pmid=39103719&amp;doi=10.1007/s00125-024-06243-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b77-dmj-2025-0242">
<span class="label">77.</span><cite>Ueda P, Soderling J, Wintzell V, Svanstrom H, Pazzagli L, Eliasson B, et al.  GLP-1 receptor agonist use and risk of suicide death. JAMA Intern Med. 2024;184:1301–12. doi: 10.1001/jamainternmed.2024.4369.</cite> [<a href="https://doi.org/10.1001/jamainternmed.2024.4369" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11372654/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39226030/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Intern%20Med&amp;title=GLP-1%20receptor%20agonist%20use%20and%20risk%20of%20suicide%20death&amp;author=P%20Ueda&amp;author=J%20Soderling&amp;author=V%20Wintzell&amp;author=H%20Svanstrom&amp;author=L%20Pazzagli&amp;volume=184&amp;publication_year=2024&amp;pages=1301-12&amp;pmid=39226030&amp;doi=10.1001/jamainternmed.2024.4369&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b78-dmj-2025-0242">
<span class="label">78.</span><cite>Shapiro SB, Yin H, Yu OH, Rej S, Suissa S, Azoulay L. Glucagon-like peptide-1 receptor agonists and risk of suicidality among patients with type 2 diabetes: active comparator, new user cohort study. BMJ. 2025;388:e080679.  doi: 10.1136/bmj-2024-080679.</cite> [<a href="https://doi.org/10.1136/bmj-2024-080679" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11863255/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40010803/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMJ&amp;title=Glucagon-like%20peptide-1%20receptor%20agonists%20and%20risk%20of%20suicidality%20among%20patients%20with%20type%202%20diabetes:%20active%20comparator,%20new%20user%20cohort%20study&amp;author=SB%20Shapiro&amp;author=H%20Yin&amp;author=OH%20Yu&amp;author=S%20Rej&amp;author=S%20Suissa&amp;volume=388&amp;publication_year=2025&amp;pages=e080679&amp;pmid=40010803&amp;doi=10.1136/bmj-2024-080679&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b79-dmj-2025-0242">
<span class="label">79.</span><cite>Bushi G, Khatib MN, Rohilla S, Singh MP, Uniyal N, Ballal S, et al.  Association of GLP-1 receptor agonists with risk of suicidal ideation and behaviour: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2025;41:e70037.  doi: 10.1002/dmrr.70037.</cite> [<a href="https://doi.org/10.1002/dmrr.70037" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11823376/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39945396/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Metab%20Res%20Rev&amp;title=Association%20of%20GLP-1%20receptor%20agonists%20with%20risk%20of%20suicidal%20ideation%20and%20behaviour:%20a%20systematic%20review%20and%20meta-analysis&amp;author=G%20Bushi&amp;author=MN%20Khatib&amp;author=S%20Rohilla&amp;author=MP%20Singh&amp;author=N%20Uniyal&amp;volume=41&amp;publication_year=2025&amp;pages=e70037&amp;pmid=39945396&amp;doi=10.1002/dmrr.70037&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b80-dmj-2025-0242">
<span class="label">80.</span><cite>Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med. 2024;30:168–76. doi: 10.1038/s41591-023-02672-2.</cite> [<a href="https://doi.org/10.1038/s41591-023-02672-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11034947/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38182782/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Med&amp;title=Association%20of%20semaglutide%20with%20risk%20of%20suicidal%20ideation%20in%20a%20real-world%20cohort&amp;author=W%20Wang&amp;author=ND%20Volkow&amp;author=NA%20Berger&amp;author=PB%20Davis&amp;author=DC%20Kaelber&amp;volume=30&amp;publication_year=2024&amp;pages=168-76&amp;pmid=38182782&amp;doi=10.1038/s41591-023-02672-2&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b81-dmj-2025-0242">
<span class="label">81.</span><cite>Chiappini S, Vickers-Smith R, Harris D, Papanti Pelletier GD, Corkery JM, Guirguis A, et al.  Is there a risk for semaglutide misuse?: focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset. Pharmaceuticals (Basel) 2023;16:994. doi: 10.3390/ph16070994.</cite> [<a href="https://doi.org/10.3390/ph16070994" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10384093/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37513906/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Pharmaceuticals%20(Basel)&amp;title=Is%20there%20a%20risk%20for%20semaglutide%20misuse?:%20focus%20on%20the%20Food%20and%20Drug%20Administration%E2%80%99s%20FDA%20Adverse%20Events%20Reporting%20System%20(FAERS)%20Pharmacovigilance%20Dataset&amp;author=S%20Chiappini&amp;author=R%20Vickers-Smith&amp;author=D%20Harris&amp;author=GD%20Papanti%20Pelletier&amp;author=JM%20Corkery&amp;volume=16&amp;publication_year=2023&amp;pages=994&amp;pmid=37513906&amp;doi=10.3390/ph16070994&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b82-dmj-2025-0242">
<span class="label">82.</span><cite>Athauda D, Maclagan K, Skene SS, Bajwa-Joseph M, Letchford D, Chowdhury K, et al.  Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390:1664–75. doi: 10.1016/S0140-6736(17)31585-4.</cite> [<a href="https://doi.org/10.1016/S0140-6736(17)31585-4" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5831666/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28781108/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Lancet&amp;title=Exenatide%20once%20weekly%20versus%20placebo%20in%20Parkinson%E2%80%99s%20disease:%20a%20randomised,%20double-blind,%20placebo-controlled%20trial&amp;author=D%20Athauda&amp;author=K%20Maclagan&amp;author=SS%20Skene&amp;author=M%20Bajwa-Joseph&amp;author=D%20Letchford&amp;volume=390&amp;publication_year=2017&amp;pages=1664-75&amp;pmid=28781108&amp;doi=10.1016/S0140-6736(17)31585-4&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b83-dmj-2025-0242">
<span class="label">83.</span><cite>Kim YK, Kim OY, Song J. Alleviation of depression by glucagon-like peptide 1 through the regulation of neuroinflammation, neurotransmitters, neurogenesis, and synaptic function. Front Pharmacol. 2020;11:1270. doi: 10.3389/fphar.2020.01270.</cite> [<a href="https://doi.org/10.3389/fphar.2020.01270" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7456867/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32922295/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Pharmacol&amp;title=Alleviation%20of%20depression%20by%20glucagon-like%20peptide%201%20through%20the%20regulation%20of%20neuroinflammation,%20neurotransmitters,%20neurogenesis,%20and%20synaptic%20function&amp;author=YK%20Kim&amp;author=OY%20Kim&amp;author=J%20Song&amp;volume=11&amp;publication_year=2020&amp;pages=1270&amp;pmid=32922295&amp;doi=10.3389/fphar.2020.01270&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b84-dmj-2025-0242">
<span class="label">84.</span><cite>Tsai WH, Sung FC, Chiu LT, Shih YH, Tsai MC, Wu SI. Decreased risk of anxiety in diabetic patients receiving glucagon-like peptide-1 receptor agonist: a nationwide, population-based cohort Study. Front Pharmacol. 2022;13:765446. doi: 10.3389/fphar.2022.765446.</cite> [<a href="https://doi.org/10.3389/fphar.2022.765446" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8904427/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35281896/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Front%20Pharmacol&amp;title=Decreased%20risk%20of%20anxiety%20in%20diabetic%20patients%20receiving%20glucagon-like%20peptide-1%20receptor%20agonist:%20a%20nationwide,%20population-based%20cohort%20Study&amp;author=WH%20Tsai&amp;author=FC%20Sung&amp;author=LT%20Chiu&amp;author=YH%20Shih&amp;author=MC%20Tsai&amp;volume=13&amp;publication_year=2022&amp;pages=765446&amp;pmid=35281896&amp;doi=10.3389/fphar.2022.765446&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b85-dmj-2025-0242">
<span class="label">85.</span><cite>Ventorp F, Bay-Richter C, Nagendra AS, Janelidze S, Matsson VS, Lipton J, et al.  Exendin-4 treatment improves LPS-induced depressive-like behavior without affecting pro-inflammatory cytokines. J Parkinsons Dis. 2017;7:263–73. doi: 10.3233/JPD-171068.</cite> [<a href="https://doi.org/10.3233/JPD-171068" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5438473/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28387682/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Parkinsons%20Dis&amp;title=Exendin-4%20treatment%20improves%20LPS-induced%20depressive-like%20behavior%20without%20affecting%20pro-inflammatory%20cytokines&amp;author=F%20Ventorp&amp;author=C%20Bay-Richter&amp;author=AS%20Nagendra&amp;author=S%20Janelidze&amp;author=VS%20Matsson&amp;volume=7&amp;publication_year=2017&amp;pages=263-73&amp;pmid=28387682&amp;doi=10.3233/JPD-171068&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b86-dmj-2025-0242">
<span class="label">86.</span><cite>Weina H, Yuhu N, Christian H, Birong L, Feiyu S, Le W. Liraglutide attenuates the depressive- and anxiety-like behaviour in the corticosterone induced depression model via improving hippocampal neural plasticity. Brain Res. 2018;1694:55–62. doi: 10.1016/j.brainres.2018.04.031.</cite> [<a href="https://doi.org/10.1016/j.brainres.2018.04.031" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29705602/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Brain%20Res&amp;title=Liraglutide%20attenuates%20the%20depressive-%20and%20anxiety-like%20behaviour%20in%20the%20corticosterone%20induced%20depression%20model%20via%20improving%20hippocampal%20neural%20plasticity&amp;author=H%20Weina&amp;author=N%20Yuhu&amp;author=H%20Christian&amp;author=L%20Birong&amp;author=S%20Feiyu&amp;volume=1694&amp;publication_year=2018&amp;pages=55-62&amp;pmid=29705602&amp;doi=10.1016/j.brainres.2018.04.031&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b87-dmj-2025-0242">
<span class="label">87.</span><cite> Food and Drug Administration (FDA). Saxenda highlights of prescribing information. Available from:  <a href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206321s016lbl.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/206321s016lbl.pdf</a> (cited 2025 Jun 11)</cite>
</li>
<li id="b88-dmj-2025-0242">
<span class="label">88.</span><cite> Novo Nordisc. How to take wegovy. Available from:  <a href="https://www.wegovy.com/taking-wegovy/how-to-use-the-wegovypen.html" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.wegovy.com/taking-wegovy/how-to-use-the-wegovypen.html</a> (cited 2025 Jun 11)</cite>
</li>
<li id="b89-dmj-2025-0242">
<span class="label">89.</span><cite>Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jodar E, Leiter LA, et al.  Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834–44. doi: 10.1056/NEJMoa1607141.</cite> [<a href="https://doi.org/10.1056/NEJMoa1607141" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27633186/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Semaglutide%20and%20cardiovascular%20outcomes%20in%20patients%20with%20type%202%20diabetes&amp;author=SP%20Marso&amp;author=SC%20Bain&amp;author=A%20Consoli&amp;author=FG%20Eliaschewitz&amp;author=E%20Jodar&amp;volume=375&amp;publication_year=2016&amp;pages=1834-44&amp;pmid=27633186&amp;doi=10.1056/NEJMoa1607141&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b90-dmj-2025-0242">
<span class="label">90.</span><cite>Yoshida Y, Joshi P, Barri S, Wang J, Corder AL, O’Connell SS, et al.  Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes: a systematic review and meta-analysis. J Diabetes Complications. 2022;36:108255. doi: 10.1016/j.jdiacomp.2022.108255.</cite> [<a href="https://doi.org/10.1016/j.jdiacomp.2022.108255" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35817678/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Diabetes%20Complications&amp;title=Progression%20of%20retinopathy%20with%20glucagon-like%20peptide-1%20receptor%20agonists%20with%20cardiovascular%20benefits%20in%20type%202%20diabetes:%20a%20systematic%20review%20and%20meta-analysis&amp;author=Y%20Yoshida&amp;author=P%20Joshi&amp;author=S%20Barri&amp;author=J%20Wang&amp;author=AL%20Corder&amp;volume=36&amp;publication_year=2022&amp;pages=108255&amp;pmid=35817678&amp;doi=10.1016/j.jdiacomp.2022.108255&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b91-dmj-2025-0242">
<span class="label">91.</span><cite>Vilsboll T, Bain SC, Leiter LA, Lingvay I, Matthews D, Simo R, et al.  Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab. 2018;20:889–97. doi: 10.1111/dom.13172.</cite> [<a href="https://doi.org/10.1111/dom.13172" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5888154/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29178519/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Obes%20Metab&amp;title=Semaglutide,%20reduction%20in%20glycated%20haemoglobin%20and%20the%20risk%20of%20diabetic%20retinopathy&amp;author=T%20Vilsboll&amp;author=SC%20Bain&amp;author=LA%20Leiter&amp;author=I%20Lingvay&amp;author=D%20Matthews&amp;volume=20&amp;publication_year=2018&amp;pages=889-97&amp;pmid=29178519&amp;doi=10.1111/dom.13172&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b92-dmj-2025-0242">
<span class="label">92.</span><cite>Bethel MA, Diaz R, Castellana N, Bhattacharya I, Gerstein HC, Lakshmanan MC. HbA1c change and diabetic retinopathy during GLP-1 receptor agonist cardiovascular outcome trials: a meta-analysis and meta-regression. Diabetes Care. 2021;44:290–6. doi: 10.2337/dc20-1815.</cite> [<a href="https://doi.org/10.2337/dc20-1815" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7783944/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33444163/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&amp;title=HbA1c%20change%20and%20diabetic%20retinopathy%20during%20GLP-1%20receptor%20agonist%20cardiovascular%20outcome%20trials:%20a%20meta-analysis%20and%20meta-regression&amp;author=MA%20Bethel&amp;author=R%20Diaz&amp;author=N%20Castellana&amp;author=I%20Bhattacharya&amp;author=HC%20Gerstein&amp;volume=44&amp;publication_year=2021&amp;pages=290-6&amp;pmid=33444163&amp;doi=10.2337/dc20-1815&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b93-dmj-2025-0242">
<span class="label">93.</span><cite>Eleftheriadou A, Riley D, Zhao SS, Austin P, Hernandez G, Lip GY, et al.  Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database. Diabetologia. 2024;67:1271–82. doi: 10.1007/s00125-024-06132-5.</cite> [<a href="https://doi.org/10.1007/s00125-024-06132-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11153282/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38584180/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetologia&amp;title=Risk%20of%20diabetic%20retinopathy%20and%20diabetic%20macular%20oedema%20with%20sodium-glucose%20cotransporter%202%20inhibitors%20and%20glucagon-like%20peptide%201%20receptor%20agonists%20in%20type%202%20diabetes:%20a%20real-world%20data%20study%20from%20a%20global%20federated%20database&amp;author=A%20Eleftheriadou&amp;author=D%20Riley&amp;author=SS%20Zhao&amp;author=P%20Austin&amp;author=G%20Hernandez&amp;volume=67&amp;publication_year=2024&amp;pages=1271-82&amp;pmid=38584180&amp;doi=10.1007/s00125-024-06132-5&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b94-dmj-2025-0242">
<span class="label">94.</span><cite>Joo JH, Sharma N, Shaia J, Wu AK, Skugor M, Singh RP, et al.  The effect of glucagon-like peptide-1 receptor agonists on diabetic retinopathy at a tertiary care center. Ophthalmol Sci. 2024;4:100547. doi: 10.1016/j.xops.2024.100547.</cite> [<a href="https://doi.org/10.1016/j.xops.2024.100547" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11321299/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39139548/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ophthalmol%20Sci&amp;title=The%20effect%20of%20glucagon-like%20peptide-1%20receptor%20agonists%20on%20diabetic%20retinopathy%20at%20a%20tertiary%20care%20center&amp;author=JH%20Joo&amp;author=N%20Sharma&amp;author=J%20Shaia&amp;author=AK%20Wu&amp;author=M%20Skugor&amp;volume=4&amp;publication_year=2024&amp;pages=100547&amp;pmid=39139548&amp;doi=10.1016/j.xops.2024.100547&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b95-dmj-2025-0242">
<span class="label">95.</span><cite>Singh H, Natt NK, Nim DK. Association between glucagon-like peptide-1 agonists and risk of diabetic retinopathy: a disproportionality analysis using FDA adverse event reporting system data. Expert Rev Endocrinol Metab. 2025;20:147–52. doi: 10.1080/17446651.2025.2459720.</cite> [<a href="https://doi.org/10.1080/17446651.2025.2459720" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39873334/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Expert%20Rev%20Endocrinol%20Metab&amp;title=Association%20between%20glucagon-like%20peptide-1%20agonists%20and%20risk%20of%20diabetic%20retinopathy:%20a%20disproportionality%20analysis%20using%20FDA%20adverse%20event%20reporting%20system%20data&amp;author=H%20Singh&amp;author=NK%20Natt&amp;author=DK%20Nim&amp;volume=20&amp;publication_year=2025&amp;pages=147-52&amp;pmid=39873334&amp;doi=10.1080/17446651.2025.2459720&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b96-dmj-2025-0242">
<span class="label">96.</span><cite>Storoni M, Chan CK, Cheng AC, Chan NC, Leung CK. The pathogenesis of nonarteritic anterior ischemic optic neuropathy. Asia Pac J Ophthalmol (Phila) 2013;2:132–5. doi: 10.1097/APO.0b013e3182902e45.</cite> [<a href="https://doi.org/10.1097/APO.0b013e3182902e45" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26108050/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Asia%20Pac%20J%20Ophthalmol%20(Phila)&amp;title=The%20pathogenesis%20of%20nonarteritic%20anterior%20ischemic%20optic%20neuropathy&amp;author=M%20Storoni&amp;author=CK%20Chan&amp;author=AC%20Cheng&amp;author=NC%20Chan&amp;author=CK%20Leung&amp;volume=2&amp;publication_year=2013&amp;pages=132-5&amp;pmid=26108050&amp;doi=10.1097/APO.0b013e3182902e45&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b97-dmj-2025-0242">
<span class="label">97.</span><cite>Hathaway JT, Shah MP, Hathaway DB, Zekavat SM, Krasniqi D, Gittinger JW, Jr, et al.  Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 2024;142:732–9. doi: 10.1001/jamaophthalmol.2024.2296.</cite> [<a href="https://doi.org/10.1001/jamaophthalmol.2024.2296" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11223051/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38958939/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JAMA%20Ophthalmol&amp;title=Risk%20of%20nonarteritic%20anterior%20ischemic%20optic%20neuropathy%20in%20patients%20prescribed%20semaglutide&amp;author=JT%20Hathaway&amp;author=MP%20Shah&amp;author=DB%20Hathaway&amp;author=SM%20Zekavat&amp;author=D%20Krasniqi&amp;volume=142&amp;publication_year=2024&amp;pages=732-9&amp;pmid=38958939&amp;doi=10.1001/jamaophthalmol.2024.2296&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b98-dmj-2025-0242">
<span class="label">98.</span><cite>Azab M, Pasina L. Semaglutide: nonarteritic anterior ischemic optic neuropathy in the FDA adverse event reporting system: a disproportionality analysis. Obes Res Clin Pract. 2025;19:77–9. doi: 10.1016/j.orcp.2025.01.011.</cite> [<a href="https://doi.org/10.1016/j.orcp.2025.01.011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39922760/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Obes%20Res%20Clin%20Pract&amp;title=Semaglutide:%20nonarteritic%20anterior%20ischemic%20optic%20neuropathy%20in%20the%20FDA%20adverse%20event%20reporting%20system:%20a%20disproportionality%20analysis&amp;author=M%20Azab&amp;author=L%20Pasina&amp;volume=19&amp;publication_year=2025&amp;pages=77-9&amp;pmid=39922760&amp;doi=10.1016/j.orcp.2025.01.011&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b99-dmj-2025-0242">
<span class="label">99.</span><cite>Abbass NJ, Nahlawi R, Shaia JK, Allan KC, Kaelber DC, Talcott KE, et al.  The effect of semaglutide and GLP-1 RAs on risk of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 2025;274:24–31. doi: 10.1016/j.ajo.2025.02.025.</cite> [<a href="https://doi.org/10.1016/j.ajo.2025.02.025" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/40015592/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Ophthalmol&amp;title=The%20effect%20of%20semaglutide%20and%20GLP-1%20RAs%20on%20risk%20of%20nonarteritic%20anterior%20ischemic%20optic%20neuropathy&amp;author=NJ%20Abbass&amp;author=R%20Nahlawi&amp;author=JK%20Shaia&amp;author=KC%20Allan&amp;author=DC%20Kaelber&amp;volume=274&amp;publication_year=2025&amp;pages=24-31&amp;pmid=40015592&amp;doi=10.1016/j.ajo.2025.02.025&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b100-dmj-2025-0242">
<span class="label">100.</span><cite>Kennedy A, Frank RN. The influence of glucose concentration and hypoxia on VEGF secretion by cultured retinal cells. Curr Eye Res. 2011;36:168–77. doi: 10.3109/02713683.2010.521968.</cite> [<a href="https://doi.org/10.3109/02713683.2010.521968" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21158590/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Curr%20Eye%20Res&amp;title=The%20influence%20of%20glucose%20concentration%20and%20hypoxia%20on%20VEGF%20secretion%20by%20cultured%20retinal%20cells&amp;author=A%20Kennedy&amp;author=RN%20Frank&amp;volume=36&amp;publication_year=2011&amp;pages=168-77&amp;pmid=21158590&amp;doi=10.3109/02713683.2010.521968&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b101-dmj-2025-0242">
<span class="label">101.</span><cite>Simo R, Hernandez C. GLP-1R as a target for the treatment of diabetic retinopathy: friend or foe? Diabetes. 2017;66:1453–60. doi: 10.2337/db16-1364.</cite> [<a href="https://doi.org/10.2337/db16-1364" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28533296/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes&amp;title=GLP-1R%20as%20a%20target%20for%20the%20treatment%20of%20diabetic%20retinopathy:%20friend%20or%20foe?&amp;author=R%20Simo&amp;author=C%20Hernandez&amp;volume=66&amp;publication_year=2017&amp;pages=1453-60&amp;pmid=28533296&amp;doi=10.2337/db16-1364&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b102-dmj-2025-0242">
<span class="label">102.</span><cite>Xiao-Yun X, Zhao-Hui M, Ke C, Hong-Hui H, Yan-Hong X. Glucagon-like peptide-1 improves proliferation and differentiation of endothelial progenitor cells via upregulating VEGF generation. Med Sci Monit. 2011;17:BR35–41. doi: 10.12659/MSM.881383.</cite> [<a href="https://doi.org/10.12659/MSM.881383" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3524715/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21278683/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Med%20Sci%20Monit&amp;title=Glucagon-like%20peptide-1%20improves%20proliferation%20and%20differentiation%20of%20endothelial%20progenitor%20cells%20via%20upregulating%20VEGF%20generation&amp;author=X%20Xiao-Yun&amp;author=M%20Zhao-Hui&amp;author=C%20Ke&amp;author=H%20Hong-Hui&amp;author=X%20Yan-Hong&amp;volume=17&amp;publication_year=2011&amp;pages=BR35-41&amp;pmid=21278683&amp;doi=10.12659/MSM.881383&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b103-dmj-2025-0242">
<span class="label">103.</span><cite>Hernandez C, Bogdanov P, Corraliza L, Garcia-Ramirez M, Sola-Adell C, Arranz JA, et al.  Topical administration of GLP-1 receptor agonists prevents retinal neurodegeneration in experimental diabetes. Diabetes. 2016;65:172–87. doi: 10.2337/db15-0443.</cite> [<a href="https://doi.org/10.2337/db15-0443" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26384381/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes&amp;title=Topical%20administration%20of%20GLP-1%20receptor%20agonists%20prevents%20retinal%20neurodegeneration%20in%20experimental%20diabetes&amp;author=C%20Hernandez&amp;author=P%20Bogdanov&amp;author=L%20Corraliza&amp;author=M%20Garcia-Ramirez&amp;author=C%20Sola-Adell&amp;volume=65&amp;publication_year=2016&amp;pages=172-87&amp;pmid=26384381&amp;doi=10.2337/db15-0443&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b104-dmj-2025-0242">
<span class="label">104.</span><cite> ClinicalTrials.gov. A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes (FOCUS). Available from:  <a href="https://clinicaltrials.gov/study/NCT03811561" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://clinicaltrials.gov/study/NCT03811561</a> (cited 2025 Jun 11)</cite>
</li>
<li id="b105-dmj-2025-0242">
<span class="label">105.</span><cite>Hashimoto Takigami N, Kuniyoshi S, Miki Y, Tamaki K, Kamada Y, Uehara K, et al.  Breast cancer, diabetes mellitus and glucagon-like peptide-1 receptor toward exploring their possible associations. Breast Cancer Res Treat. 2021;189:39–48. doi: 10.1007/s10549-021-06288-3.</cite> [<a href="https://doi.org/10.1007/s10549-021-06288-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34213657/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Breast%20Cancer%20Res%20Treat&amp;title=Breast%20cancer,%20diabetes%20mellitus%20and%20glucagon-like%20peptide-1%20receptor%20toward%20exploring%20their%20possible%20associations&amp;author=N%20Hashimoto%20Takigami&amp;author=S%20Kuniyoshi&amp;author=Y%20Miki&amp;author=K%20Tamaki&amp;author=Y%20Kamada&amp;volume=189&amp;publication_year=2021&amp;pages=39-48&amp;pmid=34213657&amp;doi=10.1007/s10549-021-06288-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b106-dmj-2025-0242">
<span class="label">106.</span><cite>Ueda P, Wintzell V, Melbye M, Eliasson B, Svensson AM, Franzen S, et al.  Use of incretin-based drugs and risk of cholangiocarcinoma: scandinavian cohort study. Diabetologia. 2021;64:2204–14. doi: 10.1007/s00125-021-05508-1.</cite> [<a href="https://doi.org/10.1007/s00125-021-05508-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8423638/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34254177/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetologia&amp;title=Use%20of%20incretin-based%20drugs%20and%20risk%20of%20cholangiocarcinoma:%20scandinavian%20cohort%20study&amp;author=P%20Ueda&amp;author=V%20Wintzell&amp;author=M%20Melbye&amp;author=B%20Eliasson&amp;author=AM%20Svensson&amp;volume=64&amp;publication_year=2021&amp;pages=2204-14&amp;pmid=34254177&amp;doi=10.1007/s00125-021-05508-1&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b107-dmj-2025-0242">
<span class="label">107.</span><cite>Bezin J, Gouverneur A, Penichon M, Mathieu C, Garrel R, Hillaire-Buys D, et al.  GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care. 2023;46:384–90. doi: 10.2337/dc22-1148.</cite> [<a href="https://doi.org/10.2337/dc22-1148" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36356111/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Care&amp;title=GLP-1%20receptor%20agonists%20and%20the%20risk%20of%20thyroid%20cancer&amp;author=J%20Bezin&amp;author=A%20Gouverneur&amp;author=M%20Penichon&amp;author=C%20Mathieu&amp;author=R%20Garrel&amp;volume=46&amp;publication_year=2023&amp;pages=384-90&amp;pmid=36356111&amp;doi=10.2337/dc22-1148&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b108-dmj-2025-0242">
<span class="label">108.</span><cite>Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al.  A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384:1113–24. doi: 10.1056/NEJMoa2028395.</cite> [<a href="https://doi.org/10.1056/NEJMoa2028395" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33185364/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=A%20placebo-controlled%20trial%20of%20subcutaneous%20semaglutide%20in%20nonalcoholic%20steatohepatitis&amp;author=PN%20Newsome&amp;author=K%20Buchholtz&amp;author=K%20Cusi&amp;author=M%20Linder&amp;author=T%20Okanoue&amp;volume=384&amp;publication_year=2021&amp;pages=1113-24&amp;pmid=33185364&amp;doi=10.1056/NEJMoa2028395&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b109-dmj-2025-0242">
<span class="label">109.</span><cite>Kim M, Kim SC, Kim J, Kim BH. Use of glucagon-like peptide-1 receptor agonists does not increase the risk of cancer in patients with type 2 diabetes mellitus. Diabetes Metab J. 2025;49:49–59. doi: 10.4093/dmj.2024.0105.</cite> [<a href="https://doi.org/10.4093/dmj.2024.0105" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11788542/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39443282/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetes%20Metab%20J&amp;title=Use%20of%20glucagon-like%20peptide-1%20receptor%20agonists%20does%20not%20increase%20the%20risk%20of%20cancer%20in%20patients%20with%20type%202%20diabetes%20mellitus&amp;author=M%20Kim&amp;author=SC%20Kim&amp;author=J%20Kim&amp;author=BH%20Kim&amp;volume=49&amp;publication_year=2025&amp;pages=49-59&amp;pmid=39443282&amp;doi=10.4093/dmj.2024.0105&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b110-dmj-2025-0242">
<span class="label">110.</span><cite>Old VJ, Davies MJ, Papamargaritis D, Choudhary P, Watson EL. The effects of glucagon-like peptide-1 receptor agonists on mitochondrial function within skeletal muscle: a systematic review. J Cachexia Sarcopenia Muscle. 2025;16:e13677.  doi: 10.1002/jcsm.13677.</cite> [<a href="https://doi.org/10.1002/jcsm.13677" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11735953/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39815782/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Cachexia%20Sarcopenia%20Muscle&amp;title=The%20effects%20of%20glucagon-like%20peptide-1%20receptor%20agonists%20on%20mitochondrial%20function%20within%20skeletal%20muscle:%20a%20systematic%20review&amp;author=VJ%20Old&amp;author=MJ%20Davies&amp;author=D%20Papamargaritis&amp;author=P%20Choudhary&amp;author=EL%20Watson&amp;volume=16&amp;publication_year=2025&amp;pages=e13677&amp;pmid=39815782&amp;doi=10.1002/jcsm.13677&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b111-dmj-2025-0242">
<span class="label">111.</span><cite>McCrimmon RJ, Catarig AM, Frias JP, Lausvig NL, le Roux CW, Thielke D, et al.  Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. Diabetologia. 2020;63:473–85. doi: 10.1007/s00125-019-05065-8.</cite> [<a href="https://doi.org/10.1007/s00125-019-05065-8" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6997246/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31897524/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Diabetologia&amp;title=Effects%20of%20once-weekly%20semaglutide%20vs%20once-daily%20canagliflozin%20on%20body%20composition%20in%20type%202%20diabetes:%20a%20substudy%20of%20the%20SUSTAIN%208%20randomised%20controlled%20clinical%20trial&amp;author=RJ%20McCrimmon&amp;author=AM%20Catarig&amp;author=JP%20Frias&amp;author=NL%20Lausvig&amp;author=CW%20le%20Roux&amp;volume=63&amp;publication_year=2020&amp;pages=473-85&amp;pmid=31897524&amp;doi=10.1007/s00125-019-05065-8&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b112-dmj-2025-0242">
<span class="label">112.</span><cite>Linge J, Birkenfeld AL, Neeland IJ. Muscle mass and glucagon-like peptide-1 receptor agonists: adaptive or maladaptive response to weight loss? Circulation. 2024;150:1288–98. doi: 10.1161/CIRCULATIONAHA.124.067676.</cite> [<a href="https://doi.org/10.1161/CIRCULATIONAHA.124.067676" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39401279/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Circulation&amp;title=Muscle%20mass%20and%20glucagon-like%20peptide-1%20receptor%20agonists:%20adaptive%20or%20maladaptive%20response%20to%20weight%20loss?&amp;author=J%20Linge&amp;author=AL%20Birkenfeld&amp;author=IJ%20Neeland&amp;volume=150&amp;publication_year=2024&amp;pages=1288-98&amp;pmid=39401279&amp;doi=10.1161/CIRCULATIONAHA.124.067676&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="b113-dmj-2025-0242">
<span class="label">113.</span><cite> ClinicalTrials.gov. Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese. Available from:  <a href="https://clinicaltrials.gov/study/NCT05616013?term=NCT05616013&amp;rank=1" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://clinicaltrials.gov/study/NCT05616013?term=NCT05616013&amp;rank=1</a> (cited 2025 Jun 11)</cite>
</li>
<li id="b114-dmj-2025-0242">
<span class="label">114.</span><cite>Hammoud R, Drucker DJ. Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1. Nat Rev Endocrinol. 2023;19:201–16. doi: 10.1038/s41574-022-00783-3.</cite> [<a href="https://doi.org/10.1038/s41574-022-00783-3" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36509857/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nat%20Rev%20Endocrinol&amp;title=Beyond%20the%20pancreas:%20contrasting%20cardiometabolic%20actions%20of%20GIP%20and%20GLP1&amp;author=R%20Hammoud&amp;author=DJ%20Drucker&amp;volume=19&amp;publication_year=2023&amp;pages=201-16&amp;pmid=36509857&amp;doi=10.1038/s41574-022-00783-3&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Diabetes &amp; Metabolism Journal are provided here courtesy of <strong>Korean Diabetes Association</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.4093/dmj.2025.0242"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/dmj-2025-0242.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (1.2 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12270588/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12270588/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12270588%2F%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12270588/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12270588/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12270588/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40631457/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12270588/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40631457/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12270588/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12270588/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="O7AUWbbUuieRJpQfq2sYbc25KT2iqCSDZI4y2Ck4Vb1cmNtzFz65uUqjEVITKCjL">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-B7-tgZZA.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-BLbQGH8u.js"></script>
    
    

    </body>
</html>
